

CURRICULUM VITAE
Stacie B. Dusetzina, PhD

Office Address

2525 West End Avenue, Suite 1203
Nashville, TN, 37205
Phone: 615-875-9281; Email: s.dusetzina@vanderbilt.edu

Education

Research Fellow 2010 – 2012
Department of Health Care Policy
Harvard Medical School

Pharmaceutical Sciences, PhD 2006 – 2010
Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy
University of North Carolina at Chapel Hill

Epidemiology, PhD Minor
University of North Carolina at Chapel Hill, Gillings School of Global Public Health

Psychology, Management & Society, Dual Majors, BA 1998-2002
University of North Carolina at Chapel Hill

Professional Experience

Professor of Health Policy 2022 - Present
Ingram Professor of Cancer Research
Vanderbilt University School of Medicine, Department of Health Policy

Associate Professor of Health Policy (Tenured) 2018 - 2022
Ingram Associate Professor of Cancer Research
Vanderbilt University School of Medicine, Department of Health Policy

Assistant Professor Division of Pharmaceutical Outcomes and Policy 2014 - 2018
University of North Carolina at Chapel Hill Eshelman School of Pharmacy

Assistant Professor of Health Policy and Management 2012 - 2018
University of North Carolina at Chapel Hill, Gillings School of Global Public Health

Assistant Professor of General Medicine and Clinical Epidemiology 2012 - 2014
University of North Carolina at Chapel Hill School of Medicine

Associate Member, Lineberger Comprehensive Cancer Center 2012 - 2018
University of North Carolina at Chapel Hill

Fellow, Cecil G. Sheps Center for Health Services Research 2012 - 2018
University of North Carolina at Chapel Hill

Clinical Trials Project Manager 2003 - 2006
Rho, Inc., Contract Research Organization, Chapel Hill, NC

Key Professional Activities

National Academies of Sciences, Engineering and Medicine Committee Member 2024 - Present
 Study: Strategies to Better Align Investments in Innovations for Therapeutic Development with Disease Burden and Unmet Needs

Invited Panelist: White House Convening on How Women are Benefitting from 2024
 President Biden's Historic Drug Law

Commissioner, Medicare Payment Advisory Commission (MedPAC) 2021 - Present

Expert Witness for Senate Aging Committee Hearing on The Complex Web 2019
 of Prescription Drug Prices:

<https://www.aging.senate.gov/hearings/the-complex-web-of-prescription-drug-prices-part-ii-untangling-the-web-and-paths-forward>

National Academies of Sciences, Engineering and Medicine Committee Member 2016, 2017
<http://www8.nationalacademies.org/cp/CommitteeView.aspx?key=49817>
 Study: Ensuring Patient Access to Affordable Drugs

Invited Participant, President's Cancer Panel Workshop 2016, 2017
<http://www.aspph.org/unc-faculty-member-invited-to-inform-presidents-cancer-panel-about-cancer-drug-pricing-and-access/>

Bibliography**Refereed Papers**

(* = Role as Faculty Mentor; ** = Lead Methodologist)

1. **Dusetzina SB**. Improving the Affordability of Prescription Drugs for Medicare Beneficiaries. JAMA Intern Med. 2024 Dec 23. doi: 10.1001/jamainternmed.2024.6915. Epub ahead of print. PMID: 39714864.
2. Blendon RJ, Blumenthal D, Glied S, Sommers BD, Rosenthal MB, McWilliams JM, **Dusetzina SB**, Figueroa JF, Yearby R, Alsan M, Kim JJ, Rubin EJ. Critical Health Care Challenges for the Next U.S. President. N Engl J Med. 2024 Oct 17;391(15):e36. doi: 10.1056/NEJMp2412959. PMID: 39413384.
3. **Dusetzina SB**, David FS. Cancer Drug Access and Innovation Under the Inflation Reduction Act-A Balancing Act. JAMA Oncol. 2024 Oct 24. doi: 10.1001/jamaoncol.2024.4745. Epub ahead of print. PMID: 39446358.
4. Jazowski SA, Nayak RK, **Dusetzina SB***. The high costs of anticancer therapies in the USA: challenges, opportunities and progress. Nat Rev Clin Oncol. 2024 Dec;21(12):888-899. doi: 10.1038/s41571-024-00948-1. Epub 2024 Oct 4. Erratum in: Nat Rev Clin Oncol. 2024 Dec;21(12):903. doi: 10.1038/s41571-024-00958-z. PMID: 39367130.
5. McWilliams JM, **Dusetzina SB**. Affordability of Health Care in the United States - Old Problems Awaiting a New Administration. N Engl J Med. 2024 Oct 17;391(15):1372-1374. doi: 10.1056/NEJMp2410638. Epub 2024 Oct 2. PMID: 39357040.

6. Glaus CEG, Serra-Burriel M, **Dusetzina SB**, Vokinger KN. Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011-2022). *Ann Intern Med*. 2024 Oct;177(10):1442-1444. doi: 10.7326/ANNALS-24-00614. Epub 2024 Sep 3. PMID: 39222511.
7. Wang Y, Kang SY, Socal MP, **Dusetzina SB***. Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes. *J Manag Care Spec Pharm*. 2024 Sep;30(9):903-907. doi: 10.18553/jmcp.2024.30.9.903. PMID: 39213140; PMCID: PMC11365561.
8. Chen RC, Basak R, **Dusetzina S**, Usinger DS, Mohammed Z, Falchook AD, Schumacher JR, Francescatti AB, Cuddy A, Chang GJ, Kozower BD, Greenberg CC, Barber AK, Katz AJ. Posttreatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). *JNCI Cancer Spectr*. 2024 Nov 1;8(6):pkae099. doi: 10.1093/jncics/pkae099. PMID: 39383199; PMCID: PMC11560850.
9. Tran NM, McKay T, Gonzales G, **Dusetzina SB**, Fry C. Aging in isolation: Sexual orientation differences in navigating cognitive decline. *SSM Popul Health*. 2024 Jul 14;27:101699. doi: 10.1016/j.ssmph.2024.101699. PMID: 39139827; PMCID: PMC11320599.
10. Choi D, Zuckerman AD, Gerzenshtein S, Katsivalis KV, Nichols PJ, Saknini MC, Schneider MP, Taylor P, **Dusetzina SB***. A primer on copay accumulators, copay maximizers, and alternative funding programs. *J Manag Care Spec Pharm*. 2024 Aug;30(8):883-896. doi: 10.18553/jmcp.2024.30.8.883. PMID: 39088335; PMCID: PMC11293768.
11. Jazowski SA, Achola EM, Nicholas LH, Wood WA, Friese CR, **Dusetzina SB***. Comparing Medicare plan selection among beneficiaries with and without a history of cancer. *Health Aff Sch*. 2024 Feb 1;2(2):qxae014. doi: 10.1093/haschl/qxae014. PMID: 38756548; PMCID: PMC10986255.
12. Vokinger KN, Nussli E, **Dusetzina SB**. Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany. *JAMA Intern Med*. 2024 Sep 1;184(9):1002-1004. doi: 10.1001/jamainternmed.2024.2559. PMID: 39008326.
13. Hart K, Medvecz AJ, Vaidya A, **Dusetzina S**, Leech AA, Wiese AD. Opioid and non-opioid analgesic regimens after fracture and risk of serious opioid-related events. *Trauma Surg Acute Care Open*. 2024 Jul 14;9(1):e001364. doi: 10.1136/tsaco-2024-001364. PMID: 39021730; PMCID: PMC11253739.
14. Conti RM, McCue S, Dockter T, Gunn HJ, **Dusetzina SB**, Bennett AV, Rapkin B, Gracia G, Jazowski S, Johnson M, Behrens R, Richardson P, Subbiah N, Chow S, Chang GJ, Neuman HB, Weiss ES. Self-Reported Financial Difficulties Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia Treated at U.S. Community Oncology Clinics (Alliance A231602CD). *medRxiv [Preprint]*. 2024 Sep 18:2024.09.13.24311098. doi: 10.1101/2024.09.13.24311098. PMID: 39371185; PMCID: PMC11451638.
15. Mitchell AP, Kinlaw AC, Peacock-Hinton S, **Dusetzina SB**, Winn AN, Sanoff HK, Lund JL. Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments. *Oncologist*. 2024 Jun 3;29(6):527-533. doi: 10.1093/oncolo/oyae035. PMID: 38484395; PMCID: PMC11144993.

16. Rathi VK, Soler ZM, Schlosser RJ, Workman AD, Chapurin N, Rowan NR, **Dusetzina SB***. The Inflation Reduction Act: Implications for Medicare spending and access to biologic therapies for chronic rhinosinusitis with nasal polyposis and asthma. *Int Forum Allergy Rhinol*. 2024 Jul;14(7):1261-1265. doi: 10.1002/alr.23344. Epub 2024 Mar 11. PMID: 38465800.
17. Gupta A, Chant ED, Mohile S, Vogel RI, Parsons HM, Blaes AH, Booth CM, Rocque GB, **Dusetzina SB**, Ganguli I. Health Care Contact Days Among Older Cancer Survivors. *JCO Oncol Pract*. 2024 Jul;20(7):943-952. doi: 10.1200/OP.23.00590. Epub 2024 Mar 7. PMID: 38452315; PMCID: PMC11268556.
18. Kagalwalla S, Tsai AK, George M, Waldock A, Davis S, Jewett P, Vogel RI, Ganguli I, Booth C, **Dusetzina SB**, Rocque GB, Blaes AH, Gupta A. Consuming Patients' Days: Time Spent on Ambulatory Appointments by People With Cancer. *Oncologist*. 2024 May 3;29(5):400-406. doi: 10.1093/oncolo/oyae016. PMID: 38339991; PMCID: PMC11067814.
19. **Dusetzina SB**. Medicare Part D Payments for Generic Imatinib From 2017 to 2023. *JAMA Intern Med*. 2024 Jan 1;184(1):104-105. doi: 10.1001/jamainternmed.2023.3932. PMID: 37983024; PMCID: PMC10660232.
20. Sinaiko AD, Lewis DM, Ho YX, **Dusetzina SB**, Packer S, Kumar VS, Keating NL. Designing a Digital Tool to Inform Oncology Practices About Cancer Treatment Cost Burdens. *JCO Clin Cancer Inform*. 2023 Sep;7:e2300022. doi: 10.1200/CCI.23.00022. PMID: 38086014; PMCID: PMC10715805.
21. Harrison NJ, Samuels LR, **Dusetzina SB**, Alexopoulos SP, Ziogas IA, Hawkins AT. The Association Between Solid Organ Transplant and Recurrence of Acute Diverticulitis: A National Assessment. *Ann Surg*. 2023 Nov 20. doi: 10.1097/SLA.0000000000006151. Epub ahead of print. PMID: 37982509.
22. Waitman LR, Bailey LC, Becich MJ, Chung-Bridges K, **Dusetzina SB**, Espino JU, Hogan WR, Kaushal R, McClay JC, Merritt JG, Rothman RL, Shenkman EA, Song X, Nauman E. Avenues for Strengthening PCORnet's Capacity to Advance Patient-Centered Economic Outcomes in Patient-Centered Outcomes Research (PCOR). *Med Care*. 2023 Dec 1;61(12 Suppl 2):S153-S160.
23. Mitchell AP, **Dusetzina SB**, Mishra Meza A, Trivedi NU, Bach PB, Winn AN. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study. *BMJ*. 2023 Oct 25;383:e075512. doi: 10.1136/bmj-2023-075512. PMID: 37879723; PMCID: PMC10599253.
24. Shapiro K, **Dusetzina SB**, Brucker BM, Escobar CM. Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities. *Urology*. 2023 Sep 30:S0090-4295(23)00839-7. doi: 10.1016/j.urology.2023.09.020. Epub ahead of print. PMID: 37778479.
25. Patel VR, Ramesh V, Tsai AK, Sedhom R, Westanmo AD, Blaes AH, Vogel RI, Parsons HM, Hanna TP, Ganguli I, **Dusetzina SB**, Rocque GB, Booth CM, Gupta A. Health Care Contact Days Experienced by Decedents With Advanced GI Cancer. *JCO Oncol Pract*. 2023 Nov;19(11):1031-1038. doi: 10.1200/OP.23.00232. Epub 2023 Sep 22. PMID: 37738532.

26. Hooper M, Reinhart M, **Dusetzina SB**, Walsh C, Griffith KN. Trends in U.S. self-reported health and self-care behaviors during the COVID-19 pandemic. *PLoS One*. 2023 Sep 19;18(9):e0291667. doi: 10.1371/journal.pone.0291667. PMID: 37725598; PMCID: PMC10508610.
27. Everson J, Besaw RJ, Whitmore CC, Joseph Mattingly T 2nd, Sinaiko AD, Keating NL, Everson NS, **Dusetzina SB**. Quality of Medication Cost Conversations and Interest in Future Cost Conversations Among Older Adults. *J Gen Intern Med*. 2023 Sep 14. doi: 10.1007/s11606-023-08388-w. Epub ahead of print. PMID: 37709993.
28. Leech AA, McNeer E, Roberts AW, **Dusetzina SB**, Lai P, Morgan JR, Patrick SW. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder. *JAMA Intern Med*. 2023 Sep 1;183(9):1023-1026. doi: 10.1001/jamainternmed.2023.2826. PMID: 37548972; PMCID: PMC10407758.
29. Boos EW, Horta M, Thompson I, **Dusetzina SB**, Leech AA. Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020. *JAMA*. 2023 Aug 22;330(8):766-3. doi: 10.1001/jama.2023.13628. PMID: 37477929; PMCID: PMC10445186.
30. Kyle MA, **Dusetzina SB**, Keating NL. Utilization Management Trends in Medicare Part D Oncology Drugs, 2010-2020. *JAMA*. 2023 Jul 18;330(3):278-280. doi: 10.1001/jama.2023.10753. PMID: 37462712; PMCID: PMC10354675.
31. **Dusetzina SB**, Keating NL, Huskamp HA, Mello MM. Medicare's Plan for Drug-Price Negotiation - The Importance of Defining Generic Entry. *N Engl J Med*. 2023 Jul 8. Epub ahead of print. PMID: 37428191.
32. Joyce DD, Schulte PJ, Kwon ED, **Dusetzina SB***, Moses KA, Sharma V, Penson DF, Tilburt JC, Boorjian SA. Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment. *J Urol*. 2023 Aug;210(2):290-298. Epub 2023 Jul 7. PMID: 37416955.
33. Jazowski SA, Vaidya AU, Donohue JM, **Dusetzina SB***, Sachs RE. Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products in 2019. *JAMA Intern Med*. 2023 Jul 10:e232381. Epub ahead of print. PMID: 37428489; PMCID: PMC10334293.
34. Cortese BD, **Dusetzina SB***, Al Awamlh BAH, Penson DF, Chang SS, Barocas DA, Luckenbaugh AN, Scarpato KR, Moses KA, Talwar R. Estimating the Impact of the Inflation Reduction Act on the Out-of-pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer. *Urol Pract*. 2023 Jul 3:101097UPJ0000000000000425. Epub ahead of print. PMID: 37409930.
35. Baig K, **Dusetzina SB***, Kim DD, Leech AA. Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. *N Engl J Med*. 2023 Mar 16;388(11):961-963. Epub 2023 Mar 11. PMID: 36912541.
36. Zuckerman AD, Schneider MP, **Dusetzina SB***. Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs. *JAMA Intern Med*. 2023 Jul 1;183(7):635-636. PMID: 37252717.

37. Jazowski SA, Vaidya AU, Donohue JM, **Dusetzina SB***, Sachs RE. Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US. *JAMA Intern Med.* 2023 Jul 1;183(7):737-739. PMID: 37213097; PMCID: PMC10203965.
38. Joyce DD, Qin X, Sharma V, Boorjian SA, Barocas DA, **Dusetzina SB***, Moses KA. The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer. *J Urol.* 2023 Jun 21:101097JU00000000000003592. Epub ahead of print. PMID: 37341420.
39. Cortese BD, **Dusetzina SB***, Luckenbaugh AN, Al Hussein Al Awamlh B, Stimson CJ, Barocas DA, Penson DF, Chang SS, Talwar R. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. *J Clin Oncol.* 2023 Jun 8:JCO2300079. Epub ahead of print. PMID: 37290029.
40. Johnson M, Kishore S, Nayak RK, **Dusetzina SB***. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease? *Curr Cardiol Rep.* 2023 Jun;25(6):577-581. Epub 2023 Apr 25. PMID: 37097432.
41. Reitsma MB, **Dusetzina SB**, Ballreich JM, Trujillo AJ, Mello MM. Examining Opportunities to Increase Savings From Medicare Price Negotiations. *JAMA Intern Med.* 2023 Jun 1;183(6):581-588. PMID: 37067794; PMCID: PMC10111230.
42. Jazowski SA, Samuel-Ryals CA, Wood WA, Zullig LL, Trogdon JG, **Dusetzina SB***. Association between low-income subsidies and inequities in orally administered antimyeloma therapy use. *Am J Manag Care.* 2023 May;29(5):246-254. PMID: 37229783; PMCID: PMC10268034.
43. **Dusetzina SB**, Besaw RJ, Whitmore CC, Mattingly TJ 2nd, Sinaiko AD, Keating NL, Everson J. Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022. *JAMA Netw Open.* 2023 May 1;6(5):e2314211. PMID: 37200029; PMCID: PMC10196872.
44. Baig K, **Dusetzina SB***. Premiums and Out-of-Pocket Spending for Long-acting Insulins Under the Medicare Part D Senior Savings Model. *JAMA.* 2022 Nov 11:e2217232. Epub ahead of print. PMID: 36368009; PMCID: PMC9652766.
45. Mattingly TJ, Everson J, Besaw RJ, Whitmore CC, Henderson SC, **Dusetzina SB**. "Worth it if you could afford it": Patient perspectives on integrating real-time benefit tools into drug cost conversations. *J Am Geriatr Soc.* 2023 Jan 13. PMID: 36637794.
46. Joyce DD, **Dusetzina SB**. Financial toxicity of oral therapies in advanced prostate cancer. *Urol Oncol.* 2023 Apr 5:S1078-1439(23)00088-1. Epub ahead of print. PMID: 37029039.
47. Johnson M, Nayak RK, Gilstrap L, **Dusetzina SB***. Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act. *JAMA Cardiol.* 2023 Jan 11. PMID: 36630145.

48. Essien UR, Lusk JB, **Dusetzina SB**. Cost-Sharing Reform for Chronic Disease Treatments as a Strategy to Improve Health Care Equity and Value in the US. *JAMA Health Forum*. 2022 Dec 2;3(12):e224804. PMID: 36580324.
49. Etteldorf A, Sedhom R, Rotolo SM, Vogel RI, Booth CM, Blaes AH, Virnig BA, **Dusetzina SB**, Gupta A. The least costly pharmacy for cancer supportive care medications over time: the logistic toxicity of playing catch up. *Support Care Cancer*. 2022 Dec 13;31(1):3. PMID: 36512134; PMCID: PMC9745713.
50. Sachs RE, Donohue JM, **Dusetzina SB**. Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs. *JAMA Health Forum*. 2022 Nov 4;3(11):e224115. PMID: 36399351.
51. **Dusetzina SB**, Huskamp HA, Qin X, Keating NL. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019. *JAMA*. 2022 Oct 18;328(15):1515-1522. PMID: 36255428.
52. **Dusetzina SB**, Huskamp HA. Impending Relief for Medicare Beneficiaries – The Inflation Reduction Act. *N Engl J Med*. 2022 Oct 20;387(16):1437-1439. PMID: 36251774.
53. Joyce DD, Sharma V, Jiang DH, Van Houten HK, Sangaralingham LR, Borah BJ, Kwon ED, Penson DF, **Dusetzina SB**, Tilburt JC, Boorjian SA. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. *J Urol*. 2022 Nov;208(5):987-996.
54. Shafer PR, **Dusetzina SB**, Sabik LM, Platts-Mills TF, Stearns SC, Trogdon JG. High Deductible Health Plans and Use of Free Preventive Services Under the Affordable Care Act. *Inquiry*. 2023 Jan-Dec;60:469580231182512. doi: 10.1177/00469580231182512. PMID: 37329296; PMCID: PMC10278429.
55. Gupta A, Arora N, Haque W, Hussaini SMQ, Sedhom R, Blaes AH, **Dusetzina SB***. Out-of-pocket costs of oral anticancer drugs for Medicare beneficiaries vary by strength and formulation. *J Geriatr Oncol*. 2022 Oct 10:S1879-4068(22)00235-1. PMID: 36229377.
56. Shafer PR, Horný M, **Dusetzina SB**. Monthly Cost-Sharing Limits and Out-of-pocket Costs for Commercially Insured Patients in the US. *JAMA Netw Open*. 2022 Sep 1;5(9):e2233006. PMID: 36107430; PMCID: PMC9478767.
57. Hwang TJ, Kesselheim AS, **Dusetzina SB**. Reforming Patient Cost Sharing for Cancer Medications in Medicare Part D. *JAMA Oncol*. 2022 Aug 4. Epub ahead of print. PMID: 35925591.
58. Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, **Dusetzina SB***. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. *Int Forum Allergy Rhinol*. 2022 Oct;12(10):1295-1298.
59. Everson J, Whitmore C, Mattingly TJ, Sinaiko A, **Dusetzina SB**. Physician Perspectives on Implementation of Real-Time Benefit Tools: A Qualitative Study. *Appl Clin Inform*. 2022 Sep 19.

60. Etteldorf A, Rotolo S, Sedhom R, Vogel RI, Blaes A, **Dusetzina SB**, Virnig B, Gupta A. Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. *JCO Oncol Pract*. 2022 Aug;18(8):e1342-e1349. PMID: 35623024; PMCID: PMC9377721.
61. Haque W, Chencheri S, Virnig BA, Blaes AH, Booth CM, **Dusetzina SB**, Gupta A. Price Comparison of Human and Veterinary Formulations of Common Medications. *JAMA Intern Med*. 2022 Sep 12. doi: 10.1001/jamainternmed.2022.3938. Epub ahead of print. PMID: 36094526.
62. Gupta A, Antonarakis ES, Blaes AH, Booth CM, **Dusetzina SB**. Evaluation of Medicare Coverage and Estimated Out-of-Pocket Costs for Generic Abiraterone Products. *JAMA Netw Open*. 2022 Sep 1;5(9):e2231475. doi: 10.1001/jamanetworkopen.2022.31475. PMID: 36178694.
63. Hussaini SMQ, Gupta A, **Dusetzina SB**. What Should I Know About Coverage With Medicare Part D? *JAMA Intern Med*. 2022 Sep 1;182(9):1016. doi: 10.1001/jamainternmed.2022.2880. PMID: 35877090.
64. Hussaini SMQ, Sedhom R, **Dusetzina SB**, Gupta A. Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches. *J Palliat Med*. 2022 Sep;25(9):1335-1337. doi: 10.1089/jpm.2022.0241. Epub 2022 Jun 28. PMID: 35763285.
65. Sachs RE, Donohue JM, **Dusetzina SB**. Accelerated Approval - Taking the FDA's Concerns Seriously. *N Engl J Med*. 2022 Jul 21;387(3):199-201. doi: 10.1056/NEJMp2204487. Epub 2022 Jul 6. PMID: 35793197.
66. Sachs RE, Jazowski SA, Gavulic KA, Donohue JM, **Dusetzina SB**. Medicaid and Accelerated Approval: Spending on Drugs with and without Proven Clinical Benefits. *J Health Polit Policy Law*. 2022 Jul 14:10041107. doi: 10.1215/03616878-10041107. Epub ahead of print. PMID: 35867545.
67. **Dusetzina SB**. Your Money or Your Life - The High Cost of Cancer Drugs under Medicare Part D. *N Engl J Med*. 2022 Jun 9;386(23):2164-2167. Epub 2022 May 4. PMID: 35507526.
68. **Dusetzina SB**, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. *Health Affairs*. 2022 April 4. *Health Affairs In 2022: Editor's Picks*
69. Everson J, Henderson SC, Cheng A, Senft N, Whitmore C, **Dusetzina SB**. Demand for and Occurrence of Medication Cost Conversations: A Narrative Review. *Med Care Res Rev*. 2022 Jul 8:10775587221108042. doi: 10.1177/10775587221108042. Epub ahead of print. PMID: 35808853.
70. Hussaini SMQ, Gupta A, **Dusetzina SB***. Financial Toxicity of Cancer Treatment. *JAMA Oncol*. 2022 May 1;8(5):788. PMID: 35266966.
71. Chino F, Carroll A, Sanger-Katz M, **Dusetzina SB**, Zafar SY. Communicating Research to Non-Researcher Audiences: A Panel Discussion From the National Cancer Institute's Future of Cancer Health Economics Research Conference. *J Natl Cancer Inst Monogr*. 2022 Jul 5;2022(59):64-67. doi: 10.1093/jncimonographs/lgab021. PMID: 35788377; PMCID: PMC9255936.

72. Das RK, **Dusetzina SB***. Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013-2019. *J Gen Intern Med*. 2022 Jun 13. doi: 10.1007/s11606-022-07693-0. Epub ahead of print. PMID: 35697969.
73. Kyle MA, **Dusetzina SB**, Keating NL. Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020. *JAMA Netw Open*. 2022 Jul 1;5(7):e2221468. doi: 10.1001/jamanetworkopen.2022.21468. PMID: 35816318; PMCID: PMC9280395.
74. Shen X, Spratt DE, **Dusetzina SB**, Chen RC. Variations in Medical Necessity Determinations Across Commercial Insurance Carriers for Prostate Cancer Procedures. *Int J Radiat Oncol Biol Phys*. 2022 Jul 30:S0360-3016(22)02597-4. doi: 10.1016/j.ijrobp.2022.07.1839. Epub ahead of print. PMID: 35918053.
75. **Dusetzina SB**. Relief in Sight — Estimated Savings Under Medicare Part D Redesign. *New England Journal of Medicine*. 2021 Nov 10. PMID: 34758246
76. **Dusetzina SB**, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA. Patient and Payer Incentives to Use On-Patent Brand-Name Drugs Over Authorized Generics in Medicare Part D. *JAMA Internal Medicine*. 2021 Oct 18:e215997. PMID: 34661600
77. Essien UR, **Dusetzina SB**, Gellad WF. A Policy Prescription for Reducing Health Disparities-Achieving Pharmacoequity. *JAMA*. 2021 Nov 9;326(18):1793-1794. PMID: 34677579.
78. Horný M, Shafer PR, **Dusetzina SB**. Concordance of Disclosed Hospital Prices With Total Reimbursements for Hospital-Based Care Among Commercially Insured Patients in the US. *JAMA Netw Open*. 2021 Dec 1;4(12):e2137390. PMCID: PMC8669520.
79. Xiao R, Ross JS, Gross CP, **Dusetzina SB**, McWilliams JM, Sethi R, Rath V. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. *JAMA Intern Med*. 2022 Jun 1;182(6):603-611. PMID: 35435948; PMCID: PMC9016607.
80. Sachs RE, Gavulic KA, Donohue JM, **Dusetzina SB**. Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure. *JAMA Intern Med*. 2021 Dec 6:e217001. PMCID: PMC8649909.
81. Hwang TJ, Qin X, Keating NL, Huskamp HA, **Dusetzina SB***. Assessment of Out-of-Pocket Costs with Rebate Pass-Through for Brand-Name Cancer Drugs Under Medicare Part D. *JAMA Oncology*. 2021 Nov 11:e215433. PMID: 34762097
82. Etteldorf A, Rotolo S, Sedhom R, Vogel RI, Blaes A, **Dusetzina SB**, Virnig B, Gupta A. Finding the Lowest-Cost Pharmacy for Cancer Supportive Care Medications: Not So Easy. *JCO Oncol Pract*. 2022 May 27:OP2200051. PMID: 35623024.
83. Das RK, **Dusetzina SB***. Gender-Affirming Hormone Therapy Spending and Use in the USA, 2013-2019. *J Gen Intern Med*. 2022 Jun 13. PMID: 35697969.

84. Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, **Dusetzina SB**. Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. *Int Forum Allergy Rhinol*. 2022 Jan 14. PMID: 35029845.
85. Jazowski SA, Wilson L, **Dusetzina SB***, Zafar SY, Zullig LL. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma. *JAMA Netw Open*. 2022 Jun 1;5(6):e2215720. PMID: 35671056; PMCID: PMC9175078.
86. Sachs RE, Gavulic KA, Donohue JM, **Dusetzina SB**. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval. *JAMA Health Forum*. 2021 Oct 8;2(10):e213177. doi: 10.1001/jamahealthforum.2021.3177. PMID: 35977163; PMCID: PMC8727037.
87. Desai N, Besaw RJ, Sedhom R, Qasim Hussaini SM, Blaes AH, **Dusetzina SB**, Gupta A. Estimated out-of-pocket costs for cancer-directed and supportive care medications for older adults with advanced pancreatic cancer. *J Geriatr Oncol*. 2022 Jun;13(5):754-757. PMID: 35168921.
88. Lai LY, Oerline MK, Kaufman SR, Herrel LA, Skolarus TA, **Dusetzina SB**, Ellimoottil C, Shahinian VB, Hollenbeck BK, Caram MEV. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. *Urology*. 2021 Dec 1:S0090-4295(21)01103-1. PMID: 34861316.
89. Yeung K, **Dusetzina SB**, Basu A. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. *JAMA Network Open*. 2021 Jun 1;4(6):e2113393. PMID: 34125219
90. **Dusetzina SB**, Huskamp HA, Jazowski SA, Winn AN, Basch E, Keating NL. Comparison of Anticancer Medication Use and Spending Under United States Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. *JAMA Health Forum*. (In Press)
91. Pourali SP, Nshuti L, **Dusetzina SB***. Out-of-Pocket Costs of Specialty Medications for Psoriasis and Psoriatic Arthritis Treatment in the Medicare Population. *JAMA Dermatol*. 2021 Oct 1;157(10):1239-1241. PMID: 34524386; PMCID: PMC8444058.
92. **Dusetzina SB**, Elkins W, Hoadley J. Extra Help Needs a Hand: Partial Subsidies in Medicare Part D Program. *Journal of General Internal Medicine*. 2021 May 23. PMID: 34027607
93. Wallis CJD, Joyce DD, Klaassen Z, Luckenbaugh AN, Laviana AA, Penson D, **Dusetzina SB**, Barocas DA. Out-of-pocket costs for commercially insured patients with localized prostate cancer. *Urol Oncol*. 2021 Dec;39(12):797-805. PMID: 34600803.
94. Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, **Dusetzina SB***. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. *JCO Oncol Pract*. 2021 Sep 24:OP2100466. PMID: 34558297.

95. Gupta A, Premnath N, Sedhom R, Beg MS, Khera R, Laheru DA, **Dusetzina SB***. Projected 30- day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D. *Pancreatology*. 2021 Aug 21; (5): 1009-1010. PMID:34006458.
96. Mitchell AP, Mishra A, Dey P, Curry MA, Trivedi NU, Haddadin M, Rahman MW, Winn AN, **Dusetzina SB**, Bach PB. Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. *Oncologist*. 2021 May 13. PMID:33982829.
97. Auty SG, Shafer PR, **Dusetzina SB**, Griffith KN. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. *JAMA Health Forum*. (In Press)
98. Yachimski PS, Lucas A, **Dusetzina SB**. Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a SEER-Medicare database study. *Gastrointestinal Endoscopy*. 2021 Oct;94(4):752-759.e1. PMID: 33862104.
99. Samuel-Ryals, CA, Mbah, OM, Peacock-Hinton, S, Cross, SH, Reeve, BB, **Dusetzina, SB**. Evaluating the Contribution of Patient-Provider Communication and Cancer Diagnosis to Racial Disparities in End-of-Life Care among Medicare Beneficiaries. *Journal of General Internal Medicine*. 2021 Nov;36(11):3311-3320. PMID: 33963508
100. **Dusetzina SB**, Keating NL, Huskamp HA. Authorized Generics and Their Evolving Role in Prescription Drug Pricing and Access. *JAMA Internal Medicine*. 2021 Jan 25. PMID:33492347
101. **Dusetzina SB**, Cubanski J, Roberts D, Hoadley J, True S, Nshuti L, Neuman T. Trends in Medicare Part D Coverage of Generics with Equivalent Brands. *American Journal of Managed Care*. 2021 Jul;27(7):283-288. PMID: 34314117
102. **Dusetzina SB**, Muluneh B, Keating NL, Huskamp HA. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults. *New England Journal of Medicine*. 2020 Dec 10;383(24):2299-2301. PMID: 33283988
103. Chen S, Krishnan S, Shafer PR, **Dusetzina SB**, Horný H. Annual Out-Of-Pocket Spending Clusters Within Short Time Intervals: Implications For Health Care Affordability. *Health Affairs*. 2021 Feb. 40; 274-280.
104. Sachs RE, Donohue JM, **Dusetzina SB**. Confronting State Medicaid Drug Spending Pressures. *JAMA*. 2020 Oct 9. PMID: 33034613
105. Yeung K, Barthold D, **Dusetzina SB**, Basu A. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps. *New England Journal of Medicine*. 2020 Aug 6; 383(6):558-566. PMID:32757524.
106. Everson J, Cheng AK, Patrick SW, **Dusetzina SB**. Association of Electronic Prescribing of Controlled Substances With Opioid Prescribing Rates. *JAMA Netw Open*. 2020 Dec 1;3(12):e2027951. PMID: 33346845
107. Gavulic KA, **Dusetzina SB***. Prescription Drug Priorities under the Biden Administration.

J Health Polit Policy Law. 2021 Jan 22:8970810. PMID: 33503239

108. Hollenbeck BK, Oerline M, Kaufman SR, Caram MEV, **Dusetzina SB**, Ryan AM, Shahinian VB. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. *Urology*. 2020 Oct 16:S0090-4295(20)31260-7. PMID: 33075381
109. Caram MEV, Oerline MK, **Dusetzina SB**, Herrel LA, Modi PK, Kaufman SR, Skolarus TA, Hollenbeck BK, Shahinian V. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. *Cancer*. 2020 Dec 1; 126(23):5050-5059. PMID:32926427
110. **Dusetzina SB**, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available. *Health Affairs*. 2020 Aug; 39(8):1326-1333. PMID:32744944.
111. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guidelien Update. *J Clin Oncol*. 2020 Aug 20;38(24):2782-2797. PMID:32641378.
112. Gokhale M, **Dusetzina SB**, Pate V, Chun DS, Buse JB, Stürmer T, Gower EW. Decreased Antihyperglycemic Drug Use Driven by High Out-of-Pocket Costs Despite Medicare Coverage Gap Closure. *Diabetes Care*. 2020 Sep;43(9):2121-2127. PMID:32641378.
113. Shafer PR, **Dusetzina SB**, Sabik LM, Platts-Mills TF, Stearns SC, Trogdon JG. Insurance instability and use of emergency and office-based care after gaining coverage: An observational cohort study. *PLoS One*. 2020 Sep 4;15(9):e0238100. eCollection 2020. PMID: 32886675
114. Agarwal A, Roberts A, **Dusetzina SB**, Royce TJ. Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017. *JAMA Oncology*. 2020 May 29;6(8):1-4. PMID:32469405.
115. Jazowski SA, **Dusetzina SB**. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities. *Cancer*. 2020 Aug 15; 126(16):3613-3616. PMID:32438468.
116. Savitz ST, Bailey SC, **Dusetzina SB**, Jones WS, Trogdon JG, Stearns SC. Treatment selection and medication adherence for stable angina: The role of area-based health literacy. *J Eval Clin Pract*. 2020 Dec;26(6):1711-1721. PMID: 31994280
117. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. *J Clin Oncol*. 2020 Aug 20;38(24):2782-2797. PMID: 32658626
118. Roberts AW, Eiffert S, Wulff-Burchfield EM, **Dusetzina SB**, Check DK. Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer. *J Natl Cancer Inst*. 2020 Aug 17:djaa122. PMID: 32805032

119. Erath A, **Dusetzina SB***. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019. *JAMA Network Open*. 2020 Apr 1;3(4). PMID:32338754.
120. **Dusetzina SB**, Huskamp HA, Keohane LM, Keating NL. Medicare Part D and Insulin Affordability-The Devil Is in the Details. *New England Journal of Medicine*. 2020 May 14;382(20):1878-1880. PMID:32237673.
121. Leech AA, Neumann PJ, Cohen JT, Jagasia M, **Dusetzina SB**. Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the US. *The Oncologist*. 2020 Jul;25(7):e1117-e1119. PMID:32386072.
122. Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, **Dusetzina SB**, Wiltshire T. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. *Value Health*. 2020 Jan;23(1):61-73. PMID: 31952675
123. Hollenbeck BK, Oerline M, Kaufman SR, Caram MEV, **Dusetzina SB**, Ryan AM, Shahinian VB. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. *Urology*. 2020 Oct 16:S0090-4295(20)31260-7. PMID: 33075381
124. Cole AL, Wood WA, Muluneh B, Lund JL, Elston Lafata J, **Dusetzina SB***. Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib. *Journal of Oncology Practice*. 2020 May; 16(5):e443-3445. PMID:32196424.
125. Conti R, **Dusetzina SB**, Sachs R. How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts: A look back at the ACA's successes and missed opportunities at improving prescription drug affordability. *Health Affairs*. 2020.
126. Ramsey SD, **Dusetzina SB**. Weighing Costs and Benefits in the Economics of Cancer Care. *J Clin Oncol*. 2020 Feb 1;38(4):289-291. PMID: 31804863
127. Nguyen JT, Cole AL, Leech AA, Wood WA, **Dusetzina SB***. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. *Value Health*. 2020 Oct;23(10):1292-1299. PMID: 33032772
128. Gavulic KA, Pelletier-Fleury N, **Dusetzina SB***. Peer Comparisons for Drug Price Setting: Why International Reference Pricing May Not Provide Optimal Prices. *JAMA Health Forum*. 2020.
129. **Dusetzina SB**, Oberlander J. Advancing Legislation on Drug Pricing - Is There a Path Forward? *New England Journal of Medicine*. 2019 Nov 28;381(22):2081-2084. PMID: 31774951
130. Everson J, Frisse M, **Dusetzina SB**. Real-Time Benefit Tools for Drug Prices. *JAMA*. 2019;322(24): 2383-2384. PMID: 31651954
131. Chou YT, Farley JF, Stinchcombe TE, Proctor AE, Lafata JE, **Dusetzina SB***. The Association Between Medicare Low-income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer. *Journal of the National Cancer Institute*. 2020 Jun 1; 112(6):637-646. PMID: 31501872

132. Cole AL, Jazowski SA, **Dusetzina SB***. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia. *Pharmacoepidemiology and Drug Safety*. 2019 Sep 11. PMID: 31507005
133. **Dusetzina SB**, Keating NL, Huskamp HA. Proposals to Redesign Medicare Part D -- Easing the Burden of Rising Drug Prices. *New England Journal of Medicine*. 2019 Oct 10;381(15):1401-1404. PMID:31483987
134. **Dusetzina SB**, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancer. *J Natl Cancer Inst*. 2020 Oct 1; 112(10):1055-1062. PMID: 31883008
135. Mitchell AP, Kinlaw AC, Peacock-Hinton S, **Dusetzina SB**, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. *Oncologist*. 2020 Jan;25(1):46-54. PMID: 31611329
136. Ernecoff NC, Wessell KL, Hanson LC, **Dusetzina SB**, Shea CM, Weinberger M, Bennett AV. Elements of Palliative Care in the Last 6 Months of Life: Frequency, Predictors, and Timing. *J Gen Intern Med*. 2020 Mar; 35(3):753-761. PMID: 31650402.
137. Ernecoff NC, Wessell KL, Hanson LC, Shea CM, **Dusetzina SB**, Weinberger M, Bennett AV. Does receipt of recommended elements of palliative care precede in-hospital death or hospice referral? *J Pain Symptom Manage* 2020 Apr; 59(4):778-786. PMID: 31836536
138. Henderson SC, Owino H, Thomas KC, Cyr JM, Ansari S, Glickman SW, **Dusetzina SB***. Post-discharge Health Services Use for Patients with Serious Mental Illness Treated at an Emergency Department Versus a Dedicated Community Mental Health Center. *Adm Policy Ment Health*. 2020 May; 47(3):443-450. PMID: 31813067
139. Wang LK, Quach HT, Moodabigil NV, Davis EJ, Sosman JA, **Dusetzina SB**, Johnson DB. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. *Cancer*. 2020 Jan 15;126(2):322-328. PMID: 31580492
140. **Dusetzina SB**, Huskamp HA, Keating NL. Specialty Drug Pricing and Out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Medicare Part D, 2010 to 2019. *JAMA*. 2019. 321(30).
141. **Dusetzina SB**, Bach PB. Prescription Drugs-List Price, Net Price, and the Rebate Caught in the Middle. *JAMA*. 2019 Mar 6. PMID: 30840047.
142. Hwang TJ, **Dusetzina SB**, Feng J, Maini L, Kesselheim AS. Price Increases of Protected-Class Drugs in Medicare Part D, Relative to Inflation, 2012-2017. *JAMA*. 2019 July 16; 322(3):267-269. PMID:31310287.
143. Ernecoff NC, Wessell KL, Hanson LC, Lee AM, Shea CM, **Dusetzina SB**, Weinberger M, Bennett AV. Electronic Health Record Phenotypes for Identifying Patients with Late-Stage Disease: a Method for Research and Clinical Application. *J Gen Intern Med*. 2019. August 8.

144. Savitz ST, Dobler CC, Shah ND, Bennett AV, Bailey SC, **Dusetzina SB**, Jones WS, Stearns SC, Montori VM. Patient-Clinician Decision Making for Stable Angina: The Role of Health Literacy. *EGEMS*. 2019. August 9.
145. Bushnell GA, Gaynes BN, Compton SN, Dusetzina SB, Olfson M, Sturmer T. Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth. *J Adolesc Health*. 2019 July 17.
146. Mahendraratnam N, Farley JF, Basch E, Proctor A, Wheeler SB, **Dusetzina SB***. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy. *Supportive Care Cancer*. 2019 Mar 26. PMID: 30915567
147. Mitchell AP, Winn AN, Lund JL, **Dusetzina SB***. Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. *Oncologist*. 2019 Feb 9. PMID: 30728276.
148. Pace LE, **Dusetzina SB**, Horowitz ME, Keating NL. Utilization of Long-Acting Reversible Contraceptives in the United States After vs Before the 2016 US Presidential Election. *JAMA Internal Medicine*. 2019 Feb 4. PMID: 30715075
149. **Dusetzina SB**, Mello MM. Disclosing Prescription-Drug Prices in Advertisements — Legal and Public Health Issues. *New England Journal of Medicine*. 2018 Nov 14.
150. Ellis CT, Cole AL, Sanoff HK, Hinton S, **Dusetzina SB**, Stitzenberg KB. Evaluating Surveillance Patterns after Chemoradiation-Only Compared with Conventional Management for Older Patients with Rectal Cancer. *J Am Coll Surg*. 2018 Jan 25. PMID 30685478
151. Knight TG, Deal AM, **Dusetzina SB**, Muss HB, Choi SK, Bensen JT, Williams GR. Financial Toxicity in Adults with Cancer: Adverse Outcomes and Noncompliance. *Journal of Oncology Practice*. 2018 Oct 24. PMID:30355027
152. Olszewski AJ, **Dusetzina SB**, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. *Journal of Clinical Oncology*. 2018 Aug 16. PMID:30113885
153. Pinheiro L, Check DK, Rosenstein DL, Reeder-Hayes KE, **Dusetzina SB***. Examining Potential Gaps in Supportive Medication Use for U.S. and Foreign Born Hispanic Women with Breast Cancer. *Supportive Care in Cancer*. 2018 Aug 10. PMID:30097792
154. Bushnell GA, Gaynes BN, Compton SN, **Dusetzina SB**, Brookhart MA, Sturmer T. Incidence of mental health hospitalizations, treated self-harm, and emergency room visits following new anxiety disorder diagnoses in privately insured U.S. children. *Depression and Anxiety*. 2018 Oct 24. PMID:30358025
155. Check DK, Kwan ML, Chawla N, **Dusetzina SB**, Valice E, Ergas IJ, Roh JM, Kolevska T, Rosenstein DL, Kushi LH. Opportunities to Improve Detection and Treatment of Depression among Patients with Breast Cancer Treated in an Integrated Delivery System. *J Pain Symptom Manage*. 2018 Nov 30. PMID:30508637

156. Bushnell GA, **Dusetzina SB**, Compton SN, Gaynes BN, Brookhart MA, Sturmer T. Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders. *Journal of Child and Adolescent Psychopharmacology*. 2018 Dec 19. PMID: 30565956.
157. Belenky N, Pence BW, Cole SR, **Dusetzina SB**, Edmonds A, Oberlander J, Plankey M, Adedimeji A, Wilson TE, Cohen J, Cohen MH, Milam JE, Adimora AA. Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV. *AIDS Care*. 2018 Sep 6:1-8. PMID:30189747
158. Wright B, **Dusetzina SB**, Upchurch G. Medicare's Variation in Out-of-Pocket Costs for Prescriptions: The Irrational Examples of In-Hospital Observation and Home Infusion. *Journal of the American Geriatrics Society*. 2018 Sep 28. PMID:30264858
159. Hickson R, Cole AL, **Dusetzina SB***. Implications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 Diabetes. *Journal of Managed Care and Specialty Pharmacy*.
160. Cole AL, **Dusetzina SB***. Generic Price Competition for Specialty Drugs: Too Little, Too Late? *Health Affairs*. Health Aff (Millwood). 2018 May; 37(5):738-742. PMID: 29733710
161. Roberts AW, Saloner B, **Dusetzina SB***. Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends from 2003 to 2015. *Psychiatric Services*. 2018 May 8. PMID: 29734918
162. Mitchell A, Winn AN, **Dusetzina SB***. Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. *JAMA Internal Medicine*. 2018 Jun 1; 178(6):854-856. PMID: 29630687
163. **Dusetzina SB**, Cubanski J, Rowland D, Ramsey S. Improving Affordability of Specialty Drugs by Addressing Patient Out-of-Pocket Spending. *Health Affairs Prescription Drug Pricing*.
164. Spencer JC, Brewer NT, Trogdon JG, Wheeler SB, **Dusetzina SB***. Predictors of Human Papillomavirus Vaccine Follow-Through Among Privately Insured US Patients. *American Journal of Public Health*. 2018 Jul; 108(7):946-950. PMID: 29771616
165. Bushnell GA, Brookhart MA, Gaynes BN, Compton SN, **Dusetzina SB**, Stürmer T. Examining parental medication adherence as a predictor of child medication adherence in pediatric anxiety disorders. *Medical Care*. 2018 Jun; 56(6):510-519. PMID: 29668649
166. **Dusetzina SB**, Huskamp HA, Winn AN, Basch EM, Keating NL. Changes in Out-of-Pocket and Health Care Spending for Patients Using Orally-Administered Anticancer Therapy Following State Parity Law Adoption. *JAMA Oncology*. 2017 Nov 9. PMID:29121177
167. Winn AN, Keating NL, Trogdon J, Basch E, **Dusetzina SB***. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. *JAMA Oncology*. 2018 Apr 1; 4(4):580-581. PMID: 29470578
168. Belenky N, Pence BW, Cole SR, **Dusetzina SB**, Edmonds A, Oberlander J, Plankey MW, Adedimeji A, Wilson TE, Cohen J, Cohen MH, Milam JE, Golub ET, Adimora AA. Associations between Medicare

- Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles with HIV. *Medical Care*. 2018 Jan; 56(1):47-53. PMID:29227443
169. Cole AL, Sanoff HK, **Dusetzina SB***. Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies. *JAMA Internal Medicine*. 2017 Nov 1; 177(11):1679-1680. PMID:28892541
170. **Dusetzina SB**, Conti RM, Yu N, Bach PB. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. *JAMA Internal Medicine*. 2017 Aug 1; 177(8): 1185-1188. PMID: 28558108
171. Rotenstein L, **Dusetzina SB**, Keating NL. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. *Journal of Managed Care and Specialty Pharmacy*. J Manag Care Spec Pharm. 2018 Jun; 24(6):494-502. PMID: 29799324
172. Anderson C, Winn AN, **Dusetzina SB**, Nichols H. Endocrine therapy initiation among older women with ductal carcinoma in situ. *Journal of Cancer Epidemiology*. 2017; 2017:6091709. PMID:29056966
173. Smitherman AB, Mohabir D, Wilkins TM, Blatt J, Nichols HB, **Dusetzina SB***. Early Post-therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. *The Journal of Pediatrics*. 2018 Apr; 195:161-168. PMID: 29395178
174. Durham T, Hassmiller Lich K, Viera AJ, Fine JP, Mukherjee J, Weinberger MW, **Dusetzina SB**. Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. *American Journal of Cardiology*. 2017 Nov 15; 120(10):1820-1829. PMID:28867127
175. Olszewski A, **Dusetzina SB**, Davidoff A, Trivedi A. Subsidies for oral chemotherapy and use of immunomodulatory drugs among Medicare beneficiaries with myeloma. *Journal of Clinical Oncology*. 2017 Oct 10; 35(29):3306-3314. PMID:28541791
176. Reeder-Hayes K, Meyer AM, Hinton SP, Meng K, Carey LA, **Dusetzina SB**. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women with Early Stage Breast Cancer. *Journal of Clinical Oncology* . 2017 Oct 10; 35(29):3298-3305. PMID:28727517
177. Shapiro CL, Moriarty JP, **Dusetzina SB**, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). *Journal of Clinical Oncology*. 2017 Oct 12. PMID:29023215
178. Hesketh PJ, Kris MG, Basch EM, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, **Dusetzina SB**, Eng C, Feyer PC, Jordan K, Noonan K, Somerfield MR, Sparacio D, Lyman GH. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of Clinical Oncology* . 2017 Oct 1; 35(28):3240-3261. PMID:28759346
179. Bushnell GA, Compton SN, **Dusetzina SB**, Gaynes BN, Brookhart MA, Walkup JT, Rynn MA, Sturmer T. Treating pediatric anxiety: Initial use of SSRIs and other anti-anxiety prescription medications. *Journal of Clinical Psychiatry*. 2017 Oct 31. PMID:29099547

180. Barber EL, **Dusetzina SB****, Stitzenberg KB, Rossi EC, Gehrig PA, Boggess JF, Garrett JM. Variation in Neoadjuvant Chemotherapy Utilization for Epithelial Ovarian Cancer at High Volume Hospitals in the United States and Associated Survival. *Gynecologic Oncology*. 2017 Mar 30. PMID: 28366455
181. Falchook AD, **Dusetzina SB**, Tian F, Basak R, Selvam N, Chen RC. Aggressive end-of-life care for metastatic cancer patients younger than Age 65 Years. *Journal of the National Cancer Institute*. 2017 Sep 1; 109(9). PMID:28954284
182. Roberts M, **Dusetzina SB***. The Effect of a Celebrity Health Disclosure on Demand for Health Care: Trends in BRCA Testing and Subsequent Health Services Use. *Journal of Community Genetics*. 2017 Apr; 8(2):141-146. PMID: 28299592
183. Chou YT, Winn AN, Rosenstein DL, **Dusetzina SB.*** Assessing Disruptions in Adherence to Antidepressant Treatments after Breast Cancer Diagnosis. *Pharmacoepidemiology and Drug Safety*. 2017 Mar 19. PMID: 28317314
184. Mahendraratnam N, **Dusetzina SB**, Farley JF. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014. *Journal of Managed Care Pharmacy*. 2017 Mar; 23(3):355-363. PMID: 28230452
185. Ellis CT, **Dusetzina SB****, Sanoff HK, Stitzenberg KB. Long-term Survival After Chemoradiotherapy Without Surgery for Rectal Adenocarcinoma: A Word of Caution. *JAMA Oncology*. 2017 Jan 1; 3(1): 123-125. PMID: 27768159.
186. Mitchell AP, Basch EM, **Dusetzina SB*** Financial relationships with industry among National Comprehensive Cancer Network guideline authors. *JAMA Oncology*. 2016 Dec 1; 2(12): 1628-1631. PMID: 27561170.
187. Adamson A, **Dusetzina SB**. Characteristics of Medicare Payments to Dermatologists in 2013. *JAMA Dermatology*. 2016 Nov 16. PMID: 27851841
188. Winn A, Keating NL, **Dusetzina SB*** Factors Associated with Tyrosine Kinase Inhibitors Initiation and Adherence among Medicare Beneficiaries with Chronic Myeloid Leukemia. *Journal of Clinical Oncology* . 2016 Dec 20; 34(36): 4323-4328. PMID: 27998234.
189. Pace LE, **Dusetzina SB****, Keating NL. Early impact of the Affordable Care Act on oral contraceptive cost-sharing, adherence, and discontinuation. *Health Affairs*. 2016 Sep 1; 151(9):876-7. PMID: 27168235.
190. Pace LE, **Dusetzina SB****, Keating NL. Early impact of the Affordable Care Act on uptake of long-acting reversible contraceptive methods. *Medical Care*. 2016 Sep; 54(9):811-7. PMID: 27213549.
191. Check DK, Reeder-Hayes KE, Zullig LL, Weinberger M, Basch EM, **Dusetzina SB***. Examining Racial Variation in Antiemetic Use and Post-Chemotherapy Health Care Utilization for Nausea and Vomiting Among Breast Cancer Patients. *Supportive Care in Cancer*. 2016 Dec; 24(12):4839-4847. PMID:27465051

192. **Dusetzina SB**. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003–14. *Health Affairs*. 2016 Jul 07.
193. Doll KM, **Dusetzina SB****, Robinson W. Trends in Inpatient and Outpatient Hysterectomy and Oophorectomy Rates Among Commercially Insured Women in the United States, 2000 – 2014. *JAMA Surgery*. May 2016. PMID: 27168235.
194. Kilfoyle KA, Rahangdale L, **Dusetzina SB***. Low uptake of human papillomavirus vaccine among postpartum women, 2006 – 2012. *Journal of Women’s Health*. 2016 Jul 22. PMID: 27447054.
195. **Dusetzina SB**. Drug pricing trends for orally-administered anticancer medications reimbursed by commercial health plans 2000-2014. *JAMA Oncology*. 2016 Apr 28.
196. Check DK, Samuel C, Rosenstein DL, **Dusetzina SB***. Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care among Medicare Beneficiaries with Stage IV Breast Cancer. *Journal of Clinical Oncology*. May 2016. PMID: 27161968.
197. Pergolotti M, Lavery J, Reeve B, **Dusetzina SB***. The Cost of Disability: The Patient’s Financial Burden of Outpatient Occupational and Physical Therapy (**In Press**).
198. Check DK, Rosenstein DL, **Dusetzina SB***. Early Supportive Medication Use and End-of-life Care among Medicare Beneficiaries with Advanced Breast Cancer. *Supportive Care in Cancer*. 2016. Mar 19. PMID: 26994634.
199. Winn AN, **Dusetzina SB***. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. *Pharmacoepidemiology and Drug Safety*. Apr 2016. PMID:27125337.
200. Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. *Breast Cancer Research and Treatment*. 2016. Mar 11. PMID: 26968396.
201. Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. *Breast Cancer Research and Treatment*. 2016. Mar 11. PMID: 26968396.
202. Roberts MC, Bryson A, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes K, Wheeler SB. Oncologists’ Barriers and Facilitators for Oncotype DX Use: Qualitative Study. *International Journal of Technology Assessment in Health Care (In Press)*.
203. Reeder-Hayes K, Hinton SP, Meng K, Carey L, **Dusetzina SB***. Racial Disparities in Use of HER2-Targeted Therapy for Early Stage Breast Cancer. *Journal of Clinical Oncology*. 2016 April 11. PMID: 27069085.
204. Sanoff HK, Chank YK, Lund JL, O’Neil BH, **Dusetzina SB***. Sorafenib Effectiveness in Advanced HCC. *The Oncologist*. May 2016. PMID: 27185615.

205. Roberts, MC, Bryson A, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes K, Wheeler SB. Patient-Centered Communication for Discussing Oncotype DX Testing. *Cancer Investigation*. Apr 2015. PMID: 27124287.
206. Wang CC, Lu HT, **Dusetzina SB**, Wu CH. The Association between Long-term Bisphosphonate Use and the Risk of Fracture among Women Aged 50 or Older with Osteoporosis. *Journal of Women's Health*. Apr 2016. PMID: 27096405.
207. Smitherman A, Wilkins T, Blatt J, **Dusetzina SB***. Early post-therapy hospitalizations among survivors of childhood leukemia and lymphoma. *Journal of Pediatric Hematology and Oncology*. 2016 Feb 26. PMID: 26925709
208. Padula WV, Larson RA, **Dusetzina SB**, Apperley JF, Helhmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Mahon F, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Karmanos BA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. *Journal of the National Cancer Institute*. 2016 Mar 4; 108(7). PMID: 26944912
209. Ellis SD, Chen RC, **Dusetzina SB**, Wheeler SB, Jackson GL, Nielsen ME, Carpenter WR, Weinberger M. Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. *Journal of Oncology Practice*. 2016 Mar 8. PMID: 26957651
210. Roberts MC, Weinberger M, **Dusetzina SB**, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial Variation In The Uptake Of Oncotype DX Testing For Early Stage Breast Cancer. *Journal of Clinical Oncology*. 2016 Jan 10; 34(2): 130-138. PMID: 26598755
211. **Dusetzina SB**, Keating NL. Mind the Gap: Why Closing the Doughnut Hole is Insufficient for Medicare Specialty Drug Users. *Journal of Clinical Oncology*. 2016. Feb 1; 34(4): 375-80. PMID: 26644524
212. **Dusetzina SB**, Brookhart MA, Maciejewski ML. Control Outcomes and Exposures for Improving Internal Validity of Non-Randomized Studies. *Health Services Research*. 2015 Jan. PMID:25598384
213. Roberts AW, **Dusetzina SB**, Farley JF. Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient. *Journal of Comparative Effectiveness Research*. Jan 2015; 4(1):27-35. PMID:25565067
214. Calabrese C, Overman RA, **Dusetzina SB****, Hajj-Ali RA. Indeterminate QuantiFERON-TB Gold In-Tube Results in Patients with Chronic Inflammatory Diseases on Immunosuppressive Therapy. *Arthritis Care & Research*. 2014 Sep 3. PMID: 25186123
215. Stevenson DG, **Dusetzina SB**, O'Malley AJ, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP, Huskamp HA. High-Risk Medication Use by Nursing Home Residents Before and After Hospitalization. *Medical Care*. 2014 Oct; 52(10):884-90. PMID: 25185637.
216. **Dusetzina SB**, Muluneh B, Khan T, Richards KL, Keating NL. Obstacles to Affordable Cancer Treatments. (Invited Commentary). *NC Medical Journal*. 2014 Jul-Aug; 75(4):257-60. PMID: 25046090.

217. Stevenson DG, O'Malley AJ, **Dusetzina SB**, Chernew ME, Mitchell S, Zarowitz BJ, Newhouse JP, Huskamp HA. Effect of Part D Coverage Restrictions for Antidepressants, Antipsychotics and Cholinesterase Inhibitors on Related Nursing Home Resident Outcomes. *Journal of the American Geriatrics Society*. 2014 Sep; 62(9): 1666-74. PMID: 25123044.
218. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MC, Nam R, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Wooten T, **Dusetzina SB**, Virgo K. Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC): American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. *Journal of Clinical Oncology*. 2014 Oct 20; 32(30): 3436-48. PMID:25199761
219. Reeder-Hayes K, Meyer AM, **Dusetzina SB**, Liu H, Wheeler S. Racial Disparities in Initiation of Adjuvant Endocrine Therapy of Early Breast Cancer. *Breast Cancer Research and Treatment* 2014; 145(3):743-751. PMID: 24789443.
220. Pace L, **Dusetzina SB**** (Co-First Authors), Fendrick MA, Keating NL, Dalton VK. The impact of out-of-pocket costs on use of intrauterine contraception among women with employer-sponsored insurance. *Medical Care* 2013; 51: 959-963. PMID: 24036995
221. **Dusetzina SB**, Winn A, Abel G, Huskamp HA, Keating NL. Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia. *Journal of Clinical Oncology*. 2014 Feb 1; 32(4): 306-311. PMID: 24366936
222. **Dusetzina SB**, Mack C, Stürmer T. Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics. *PLOS ONE*. 2013 May 7;8(5):e63973. PMID: 23667693
223. Huskamp HA, Stevenson DG, O'Malley AJ, **Dusetzina SB**, Mitchell S, Zarowitz BJ, Chernew ME, Newhouse JP. Medicare Part D plan generosity and medication use among dual-eligible nursing home residents. *Medical Care*. 2013 Oct; 51(10):894-900. PMID: 24025658
224. **Dusetzina SB**, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in Co-Prescribing of Antidepressants and Tamoxifen among Women with Breast Cancer, 2004-2010. *Breast Cancer Research and Treatment*. 2013. Jan; 137(1):285-96. PMID: 23149465
225. Conti RM, **Dusetzina SB**, Herbert AC, Berndt EB, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. *Medical Care*. 2013 Jul; 51(7):622-627. PMID: 23605014
226. **Dusetzina SB**, Dalton VK, Chernew ME, Pace L, Bowden G, Fendrick MA. Cost of contraceptive methods to privately insured women in the United States. *Women's Health Issues*. 2013. Mar; 23(2): e69-71. PMID: 23481693
227. Ellis AR, **Dusetzina SB**, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. *Annals of Epidemiology*. 2013. Apr; 23(4):204-9. PMID: 23419508

228. Ellis AR, **Dusetzina SB**, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Investigating differences in treatment effect estimates between propensity score matching and weighting: A demonstration using STAR*D trial data. *Pharmacoepidemiology and Drug Safety*. 2013 Feb; 22(2):138-44. PMID: 23280682
229. Kornfield R, Watson S, Higashi A, Conti R, **Dusetzina SB**, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC. Effect of FDA advisories on the pharmacologic treatment of Attention Deficit Hyperactivity Disorder. *Psychiatric Services*. 2013 Apr; 1;64(4):339-46. PMID: 23318985
230. **Dusetzina SB**, Cook B, Busch AB, Alexander GC, Huskamp HA. Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with Schizophrenia. *Psychiatric Services*. 2013 Jan 1;64(1):83-7. PMID: 23280461
231. **Dusetzina SB**, Busch AB, Conti RM, Donohue, JM, Alexander GC, Huskamp, HA. Changes in Antipsychotic Use among Patients with Severe Mental Illness after an FDA Advisory. *Pharmacoepidemiology and Drug Safety*. 2012 Dec; 21(12):1251-60. PMID: 22553074
232. **Dusetzina SB**, Weinberger M, Sleath B, Gaynes BN, Farley JF, Hansen RA. Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents. *Pharmacotherapy*. 2012 Dec; 32(12):1085-94. PMID: 23208835
233. **Dusetzina SB**, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment Use and Costs among Privately-Insured Youth with New Bipolar Diagnoses. *Psychiatric Services*. 2012 Oct; 63(10):1019-25. PMID: 22855210
234. **Dusetzina SB**, Gaynes BN, Weinberger M, Farley JF, Sleath B, Hansen RA. Receipt of Guideline Concordant Pharmacotherapy among Children with New Bipolar Diagnoses. *Psychiatric Services* 2011 Dec; 62 (12): 1443-1449. PMID: 22198447
235. Gaynes BN, **Dusetzina SB**, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T. Treating depression after initial treatment failure: Directly comparing switch and augmenting strategies in STAR*D. *Journal of Clinical Psychopharmacology*. 2012 Feb; 32 (1): 114-119. PMID: 22198447
236. Katz AJ, **Dusetzina SB**, Farley JF, Ellis AR, Gaynes BN, Castillo WC, Stürmer T, Hansen RA. Distressing Adverse Events After Antidepressant Switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: Influence of Adverse Events During Initial Treatment with Citalopram on Development of Subsequent Adverse Events with an Alternative Antidepressant. *Pharmacotherapy* 2012 Mar; 32 (3): 234-243. PMID: 22392456
237. Garfield CF, Dorsey ER, Zhu S, Huskamp HA, Conti R, **Dusetzina SB**, Higashi AS, Perrin JM, Alexander GC. Trends in ambulatory diagnosis and treatment of attention deficit hyperactivity disorder in the United States, 2000-2010. *Academic Pediatrics*. 2012 Feb PMID: 22326727
238. Stang PE, Ryan PB, **Dusetzina SB**, Hartzema AG, Reich C, Overhage M, Racoosin J. Health Outcomes of Interest in Observational Data: Informing the Process for Definitions in Database Networks. *Health Outcomes Research in Medicine*. 2012 Feb; 3(1):e37-344.

239. **Dusetzina SB**, Higashi AS (Co-First Authors), Dorsey RE, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review. *Medical Care*. 2012 Jun;50(6):466-78. PMID: 22266704
240. Hansen RA, **Dusetzina SB**, Ellis AR, Stürmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment resistant depression: propensity score matched comparison of antidepressant augment and switch strategies. *General Hospital Psychiatry*. 2011 Nov. PMID: 22079151
241. Gaynes BN, Farley JF, **Dusetzina SB**, Ellis AR, Hansen RA, Miller WC, Stürmer T. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? *Anxiety and Depression*. 2011 Nov; 28(11):989-98. PMID: 21898717
242. Hansen RA, **Dusetzina SB**, Dominik RC, Gaynes, BN. Prescription refill records as a screening tool to identify antidepressant non-adherence. *Pharmacoepidemiology and Drug Safety*. 2010 Jan;19(1):33-7. PMID: 199998397
243. Farley JF, **Dusetzina SB**. Medicaid Prescription Drug Utilization and Expenditures Following Part D. *Journal of Health Care for the Poor and Underserved*. 2010; 21 (2): 715-28. PMID: 20453368
244. Hansen RA, **Dusetzina SB**, Song L, Gaynes, BN, Tu W, Murray, MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. *Journal of the American Pharmacists Association*. 2009 Nov-Dec;49(6):760-8. PMID: 19926556
245. Hansen RA, Moore CG, **Dusetzina SB**, Leinwand BI, Gartlehner G, Gaynes, BN. Controlling for Drug Dose in Systematic Review and Meta-Analysis: A Case Study of the Effect of Antidepressant Dose. *Medical Decision Making*. 2009 Jan-Feb; 29(1):91-103. PMID: 19141788

Refereed Reports

National Academies of Sciences, Engineering, and Medicine. 2017. *Making Medicines Affordable: A National Imperative*. Washington, DC: The National Academies Press. Published on: 11/30/2017. doi: <https://doi.org/10.17226/24946>.

Dusetzina SB, Tyree S, Meyer AM, Meyer A, Green L, Carpenter WR. Linking Data for Health Services Research: A Framework and Instructional Guide. AHRQ Program on Developing Evidence to Inform Decisions about Effectiveness. Contract HHS2902010000141

Book Chapters

Gross C, **Dusetzina SB**, Emanuel EJ. (Over-)Paying for Cancer Care. In: Gluck AR, Fuchs CS, editors. *A New Deal for Cancer: Lessons from a Fifty Year War*. 2021.

Mulneh B, Conti RM, Nguyen J, Cole A, Larson RA, **Dusetzina SB**. Pharmacoeconomic Considerations for Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia. In: Hehlmann R, editor. *Chronic Myeloid Leukemia*, 2nd Edition. Springer Nature Switzerland AG. 2021.

Blalock, SJ, Beard, AJ, **Dusetzina, SB** Individual/Interpersonal Models of Health and Illness Behavior; In: Rickles, NM, Wertheimer AI, Smith M, editors. Social and Behavioral Aspects of Pharmaceutical Care, 2nd. Edition. Jones and Bartlett Publishers. Sudbury, MA. 2010.

Other Peer Reviewed Media

Editorials

Essien UR, **Dusetzina SB**. Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the US. *JAMA Pediatr*. 2023 Nov 1;177(11):1117-1118. PMID: 37669068.

Dusetzina SB, Oberlander J. The Price of Progress: Managing Prescription Drug Spending. *J Health Polit Policy Law*. 2022 Jul 14:10041065. Epub ahead of print. PMID: 35867554.

Gross CP, **Dusetzina SB**. Stemming Medicare Spending on Discarded Drugs-Waste Not, Want Not? *JAMA Intern Med*. 2022 Dec 19. Epub ahead of print. PMID: 36534375.

Everson J, **Dusetzina SB**. Real-time Prescription Benefit Tools-The Promise and Peril. *JAMA Intern Med*. 2022 Sep 12. Epub ahead of print. PMID: 36094566.

Besaw RJ, **Dusetzina SB***. Persistent Prescription Drug Affordability Challenges for Medicare Beneficiaries With Multiple Chronic Conditions-What Goes Up Must Come Down? *JAMA Intern Med*. 2022 Jan 4. PMID: 34982096.

Yeung K, **Dusetzina SB***. Prescription Drug Out-of-Pocket Cost Reduction Programs: Incentives and Implications. *JAMA Intern Med*. 2021 Jun 1;181(6):765-766. PMID: 33779700.

Jazowski SA, **Dusetzina SB***. Addressing cost-related nonadherence to oral anticancer medications through health policy reform: Challenges and opportunities. *Cancer*. 2020.

Ramsey SD, **Dusetzina SB**. Weighing Costs and Benefits in the Economics of Cancer Care. *J Clin Oncol*. 2019 Dec 5. PMID: 31804863

Winn AN, **Dusetzina SB***. More Evidence on the Limited Impact of State Oral Oncology Parity Laws. *Cancer*. 2018 Dec 19. PMID: 30566761.

Jazowski SA, **Dusetzina SB***. Recommendations for Lowering Prescription Drug Spending in Public Programs. *Annals of Internal Medicine*. 2019 Nov 12. PMID: 31711129.

Mahendraratnam N, **Dusetzina SB***. Getting More Value from Outcomes-Based Contracts. *The Journal of Law, Medicine & Ethics*. 2018;46(4):964-966. doi:10.1177/1073110518821996

Leech AA, **Dusetzina SB***. Cost-Effective but Unaffordable: The CAR-T Conundrum. *Journal of the National Cancer Institute*. 2018 Dec 17. PMID: 30561705

Dusetzina SB, Alexander GC. Drug vs. class-specific black box warnings: does one bad drug spoil the bunch? *Journal of General Internal Medicine*. 2011 Jun; 26 (6): 570-572. (Editorial) PMID: 21472500

Blogs

Cliff BQ, **Dusetzina SB**. How Employers Can Help Reduce Employees' High Health Care Cost Burdens. Health Affairs Forefront, June 6, 2024. <https://www.healthaffairs.org/content/forefront/employers-can-help-reduce-employees-high-health-care-cost-burdens>

Dusetzina SB. Too Little, Too Late: Initial Launch Prices And Access To Cures For Medicaid Enrollees. May 24, 2024. <https://www.healthaffairs.org/content/forefront/too-little-too-late-initial-launch-prices-and-access-cures-medicaid-enrollees>

Dusetzina SB, Zuckerman AD, Keating NL, Huskamp HA. Medicare Part D's New Prescription Payment Plan May Not Reduce Costs For All, Health Affairs Forefront, February 8, 2024.

DOI: 10.1377/forefront.20240206.784421

Shafer PR, Anderson DM, Horny M, **Dusetzina SB**. The Practical Challenges Of Implementing Monthly Cost-Sharing Limits In Commercial Health Plans, Health Affairs Forefront, September 21, 2023.

DOI: 10.1377/forefront.20230919.926836

Mahendraratnam Lederer N, **Dusetzina SB**. Accelerated Approval—An Unexpected Pathway To Value-Based Pricing? Health Affairs Blog. 8/18/2021

<https://www.healthaffairs.org/do/10.1377/hblog20210812.337699/full/>

Dusetzina SB. Getting To Yes: Areas Of Bipartisan Agreement On Drug Pricing And Access Reforms", Health Affairs Blog, May 31, 2019. DOI: 10.1377/hblog20190530.353251

Dusetzina SB. Nonprofit drugmaker Civica Rx aims to cure a health care system ailment. The Conversation. 10/24/2018. <https://theconversation.com/nonprofit-drugmaker-civica-rx-aims-to-cure-a-health-care-system-ailment-104744>

Shafer P, **Dusetzina SB**. Looking ahead to 2018: Will a shorter open enrollment period reduce adverse selection in exchange plans? Health Affairs Blog. 4/14/2017

<http://healthaffairs.org/blog/2017/04/14/looking-ahead-to-2018-will-a-shorter-open-enrollment-period-reduce-adverse-selection-in-exchange-plans/>

Correspondence

Sanoff H, Lund J, O'Neil B, **Dusetzina SB**. Letter to the Editor: Immortal Time Bias or Sorafenib Effect in Elderly Patients with HCC? Hepatology. 2017

Other Non-Refereed Works

Newsletters

Health Affairs Insider Newsletter, 2024

Volume 1. What's up with these secret Medicare price negotiations?

Volume 2. Can we afford to cover weight loss drugs?

Volume 3. Access to cell and gene therapies in the US.

Volume 4. Paying for drugs without insurance – who wins and who loses?

Volume 5. Everyone Loves a Middleman, Said No One Ever.

Volume 6. Fair Prices are Here! Now What?

Volume 7. What has the IRA done so far and what's coming next?

Volume 8. Why Medicare Advantage is So Darn Attractive.
Health Affairs Insider Newsletter, 2025

Podcasts

PBMs. What are they hiding? Health Affairs This Week.

<https://www.healthaffairs.org/doi/10.1377/hp20240808.466820/full/>

Obesity Medications & What You'll Pay for Them – If You Can Get Them. Health Affairs This Week.

<https://www.healthaffairs.org/doi/10.1377/hp20240530.341488/full/>

What the Inflation Reduction Act Really Means for Health Care

<https://www.commonwealthfund.org/publications/podcast/2022/sep/what-inflation-reduction-act-really-means-health-care>

An Arm and A Leg: Congress fixed (a piece of) Medicare. It only took a few decades.

<https://armandalegshow.com/episode/congress-fixed-a-piece-of-medicare/>

A Health Podyssey: Stacie Dusetzina Shares Why Medicare Beneficiaries May Not Fill Specialty Drug Prescriptions. Health Affairs. 2022. <https://podcasts.apple.com/us/podcast/a-health-podyssey-stacie-dusetzina-shares-why/id1542851834?i=1000558341542>

Plenary Session with Vinay Prasad, Episode 1.67

<https://www.stitcher.com/podcast/vinay-prasad/plenary-session/e/62223311>

Let's Talk High Drug Prices with Dr. Stacie Dusetzina

Spotify: <https://open.spotify.com/episode/1nyoKTvw13ryAXPiHaI9n1?si=4I5hA8IU5FG9xHWSmUS3qg>

Healthcare Unfiltered. What to Expect From Medicare Part D in 2021

<https://soundcloud.com/user-565390384/what-to-expect-from-medicare-part-d-in-2021>

KHN's 'What the Health?': The Drug Price Dilemma

<https://khn.org/news/article/podcast-khn-what-the-health-199-drug-price-dilemma-june-3-2021/>

Health Affairs, A Health Podyssey: Timing Out-Of-Pocket Spending In Health Care Is Challenging

<https://www.healthaffairs.org/doi/10.1377/hp20210607.386764/full/>

Dusetzina SB. Financial Barriers to Cancer Care for Patients Obtaining Insurance on the Federal Exchange. Journal of Clinical Oncology Podcast for article: Access to Accredited Cancer Hospitals within Federal Exchange plans Under the Affordable Care Act. 2016.

<http://ascopubs.org/doi/suppl/10.1200/JCO.2016.69.983>

Essays

Wall Street Journal April 29, 2019

Should Drug Prices Be Disclosed in Ads Targeted Directly to Consumers? – NO

<https://www.wsj.com/articles/should-drug-prices-be-disclosed-in-ads-targeted-directly-to-consumers-11556589840>

Media Collaborations

Kaiser Health News 1/18/2019 - *Secretive 'Rebate Trap' Keeps Generic Drugs For Diabetes And Other Ills Out Of Reach*. Article includes original data.

<https://khn.org/news/secretive-rebate-trap-keeps-generic-drugs-for-diabetes-and-other-ills-out-of-reach/>

Washington Post 3/9/2016 - *This drug is defying a rare form of leukemia – and it keeps getting pricier*. Article includes my original data and was on the front page of the print edition 3/10/2016.

https://www.washingtonpost.com/business/this-drug-is-defying-a-rare-form-of-leukemia--and-it-keeps-getting-pricier/2016/03/09/4fff8102-c571-11e5-a4aa-f25866ba0dc6_story.html
<http://thewashingtonpost.newspaperdirect.com/epaper/viewer.aspx>

Washington Post 3/18/2016 - A window into one of the most baffling things about drug prices. Article includes my original data.

<https://www.washingtonpost.com/news/wonk/wp/2016/03/18/a-window-into-one-of-the-most-baffling-things-about-drug-prices/>

Podium Presentations (* Indicates Role as Faculty Mentor)
Includes only presentations as first author or of trainees.

Jazowski SA, Vaidya AU, Donohue JM, **Dusetzina SB***, Sachs RE. Commercial Health Plan and Enrollee Out-of-Pocket Spending on Accelerated Approval Products. Academy Health Annual Research Meeting, Seattle, Washington. June 2023.

Dusetzina SB, Besaw RJ, Whitmore CC, Mattingly TJ 2nd, Sinaiko AD, Keating NL, Everson J. Cost-Related Medication Nonadherence and Desire for Medication Cost Information Among Adults Aged 65 Years and Older in the US in 2022. Academy Health Annual Research Meeting, Seattle, Washington. June 2023.

Dusetzina SB, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. European Health Economics Meeting. Oslo, Norway. July 2022.

Dusetzina SB. Achieving Pharmacoequity - a Policy Prescription for Reducing Health Disparities (Invited Panelist). AcademyHealth Annual Research Meeting. Washington DC. June 2022.

Dusetzina SB, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, Walunas TL, Wood WA, Zuckerman AD, Zullig LL, Keating NL. Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions. AcademyHealth Annual Research Meeting. Washington DC. June 2022.

Dusetzina SB, Huskamp HA, Jazowski S, Winn AN, Basch E, Keating NL. Comparing Anticancer Medication Use and Spending Under Oncology Parity Laws with Versus without out-of-Pocket Spending Caps. 10th Annual Conference of the American Society of Health Economists. June 2021.

Dusetzina SB, Sarpatwari A, Carrier M, Hansen R, Keating NL, Huskamp HA. Authorized Generic Drug Coverage and Estimated Spending Under Medicare Part D. 10th Annual Conference of the American Society of Health Economists. June 2021.

Dusetzina SB, Huskamp HA, Keohane LM, Keating NL. Policy Options for Improving Insulin Affordability in the United States. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Berlin, Germany. (Oral Presentation Accepted; Cancelled Due to COVID19)

Dusetzina SB, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Coverage of Brand-Name Drugs When Generics are Available in the United States. 36th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Berlin, Germany. (Oral Presentation Accepted; Cancelled Due to COVID19)

Dusetzina SB, Huskamp HA, Keohane LM, Keating NL. Policy Options for Improving Insulin Affordability in the United States. European Health Economics Association Conference 2020. July 2020. Oslo, Norway. (Oral Presentation Accepted; Cancelled Due to COVID19)

Dusetzina SB, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Coverage of Brand-Name Drugs When Generics are Available in the United States. European Health Economics Association Conference 2020. July 2020. Oslo, Norway. (Oral Presentation Accepted; Cancelled Due to COVID19)

Dusetzina SB. (Invited Panelist): The out of Pocket Cost Crisis: How Can Researchers, Clinicians, and Policymakers Bring Affordability Back to Healthcare? AcademyHealth Annual Research Meeting. Washington DC. (Cancelled Due to COVID19)

Dusetzina SB. Huskamp HA, Keating NL. Specialty Drug Pricing, Coverage, and out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Part D, 2010 to 2018. Association for Public Policy Analysis & Management Meeting, November 2019, Denver, CO.

Dusetzina SB. Huskamp HA, Keating NL. Specialty Drug Pricing, Coverage, and out-of-Pocket Spending on Orally-Administered Anticancer Drugs in Part D, 2010 to 2018. AcademyHealth Annual Research Meeting, June 2, 2019, Washington D.C.

Jazowski SA, Patrick SW, **Dusetzina SB**.* Identifying Off-Label Pharmaceutical Company Promotion of Opioids for Cancer Pain Management. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Prague, Czech Republic. August 22-26, 2018.

Dusetzina SB. (Invited Panel with Michelle Mello, Diane Rowland, Brendan Saloner) Ensuring Access to Affordable Prescription Drugs—the National Academies of Sciences, Engineering and Medicine’s Report. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

Dusetzina SB, Jazowski SA, Cole, AL, Nguyen J. Coverage and out-of-Pocket Spending on Brand Versus Generic/Biosimilar Specialty Drugs in Medicare Part D. American Society of Health Economists. Atlanta, GA, June 10-13, 2018.

Dusetzina SB. (Invited Panel) An Overview of the National Academy’s Recommendation on Drug Access. ASCO Pre-Annual Meeting Seminar: Economics of Cancer Care. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 31, 2018.

Dusetzina SB. (Invited Panel with Norman Augustine, Robert Dubois, Guru Madhavan, Charles Phelps) Making Medicines Affordable: A National Imperative. Reflections on the National Academies Report. ISPOR 23rd Annual International Meeting, Baltimore, MD. May 22, 2018.

Dusetzina SB. (Invited Panel) Out-of-Pocket Spending and Adherence to Medications. ASCO Pre-Annual Meeting Seminar: Economics of Cancer Care, Financial Toxicity and Cost. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1, 2017.

Mitchell A, Winn AN, **Dusetzina SB***. Pharmaceutical Industry Payments and Physician Drug Selection in Oncology. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL (*Awarded Best Abstract in Category*).

Mitchell A, Winn AN, **Dusetzina SB***. Pharmaceutical Industry Payments and Physician Drug Selection in Oncology. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

Winn AN, **Dusetzina SB***. Paying More for the Same Care: Comparing Physician Office and Hospital Outpatient Department Spending for Infused Chemotherapy among Privately Insured Patients. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

Dusetzina SB. Trends in Specialty Drug Spending and Use in Commercial Health Plans in the United States: 2003-2014. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 28, 2016.

Winn AN, **Dusetzina SB***. A Complimentary Approach to Group Based Trajectory Models. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 28, 2016.

Dusetzina SB, Huskamp HA, Winn AN, Basch EB, Keating NL. The Impact of State Chemotherapy Parity Laws on Use and Spending for Oral Chemotherapy. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Mahendraratnam N, **Dusetzina SB,** Farley JF. Early Impact of Medicaid Expansion on Prescription Drug Utilization and Spending. International Society for Pharmacoeconomics and Outcomes Research, Washington D.C., May 2016. *Podium Award Finalist*.

Dusetzina SB, Huskamp HA, Winn AN, Basch EB, Keating NL. The Impact of State Chemotherapy Parity Laws on Use and Spending for Oral Chemotherapy. American Society of Health Economists, Philadelphia, PA, June 2016.

Dusetzina SB, Winn AN, Reeder-Hayes K, Maciejewski ML. Taking Medication Adherence Personally: What Does Prior Adherence Tell Us about Future Adherence? 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 25, 2015.

Winn AN, **Dusetzina SB.*** Improving Adherence Measurement for Applied Pharmacoepidemiology: Estimating the Association between Endocrine Therapy Adherence and Mortality among Women with Breast Cancer. AcademyHealth Annual Research Meeting, Minneapolis, MN. June 14-16, 2015.

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB***. Racial Differences in Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care among Elderly Women with Breast Cancer. AcademyHealth Annual Research Meeting, Minneapolis, MN. June 14-16, 2015.

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB***. Racial Differences in Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care among Elderly Women with Breast Cancer. Multinational Association of Supportive Care in Cancer, Copenhagen Denmark. June 25-27, 2015.

Dusetzina SB, Ellis SD, Freedman RA, Winn A, Chambers J, Conti RM, Alexander GC, Huskamp HA, Keating NL. Payer-Level Differences in the Response to Regulatory Actions Regarding Bevacizumab's Breast Cancer Indication Withdrawal. 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan, October 25, 2014.

Dusetzina SB, Tyree S, Meyer AM, Meyer A, Green L, Carpenter WR. Performance of Methods for Linking Registry Data to Insurance Claims when Unique Identifiers are Unavailable. 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Taipei, Taiwan, Oct 27, 2014.

Jolles MP, Haynes-Maslow L, Roberts M, **Dusetzina SB.*** Mental Health Service Use by Race and Ethnicity for Adult Patients with Co-occurring Chronic Health Care Needs, 2007-2010. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Dusetzina SB, Gaynes BN, Brookhart MA, Sturmer T, Johnsson-Funk M, Huskamp HA. Using Administrative Data to Evaluate the Clinical Equivalence of Generic versus Branded Bupropion. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 15-28, 2013.

Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in Co-Prescribing of Antidepressants and Tamoxifen among Women with Breast Cancer, 2004-2010. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain. Aug 24, 2012.

Dusetzina SB, Higashi AS, Dorsey RE, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA Risk Communications on Health Care Utilization and Health Behaviors: A Systematic Review. American Public Health Association Annual Meeting, Washington DC, November 2, 2011.

Dusetzina SB, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA. Changes in the Use of High Metabolic Risk Antipsychotics. 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago IL August 14-17,2011.

Dusetzina SB, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. Bipolar Spectrum Disorders in Commercially Insured Children: Prevalence of Diagnoses and Treatments Received. Academy Health Annual Research Meeting, Boston, MA. June 29, 2010.

Dusetzina SB, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. The Quality of Initial Medication Prescribing for Children with Bipolar I Disorder. National Research Service Award Trainees Meeting, Boston, MA. June 25, 2010.

Dusetzina SB, Hansen RA, Dominik R, Gaynes BN. Prescription Refill Records as a Screening Tool to Identify Antidepressant Non-Adherence. American Pharmacists Association (APhA) Annual Meeting & Exposition, San Antonio, TX. April 3 – 6, 2009.

Dusetzina SB, Farley JF, Hansen RA, Relationship between State Medicaid Copayment Policies and Prescription Drug Utilization. Southern Pharmacy Administration Conference; Little Rock, Arkansas. June 15-17, 2007.

Poster Presentations (* Indicates Role as Faculty Mentor)
Includes only presentations as first author or of trainees.

Besaw RJ, Everson J, Whitmore CC, Mattingly II J, Sinaiko AD, Keating NL, Everson NS, **Dusetzina SB***. Quality of Medication Cost Conversations and Interest in Future Cost Conversations Among Older Adults. Academy Health Annual Research Meeting, Seattle, Washington. June 2023.

Baig K, **Dusetzina SB***. Is the Senior Savings Model Incentivizing Insulin Users to Enroll in Medicare Advantage Plans?" Academy Health Annual Research Meeting, June 4-7, 2022, Washington, DC.

Jazowski SA, Huskamp HA, Keating NL, Wood WA, **Dusetzina SB***. Non-Initiation of Prescribed Orally-Administered Therapy for Hematologic Malignancies. Academy Health Annual Research Meeting, June 4-7, 2022, Washington, DC.

Jazowski S, Wilson L, **Dusetzina SB***, Zafar Y, Zullig L. The Role of High-Deductible Health Plans on the Use of Lenalidomide in Multiple Myeloma. AcademyHealth Annual Research Meeting. June 2021 (Virtual)

Jazowski S, Samuel-Ryals C, Wood W, Zullig L, Trogdon J, **Dusetzina SB***. Do Medicare Part D Low-Income Subsidies Narrow Disparities in Orally-Administered Antimyeloma Treatment Initiation? AcademyHealth Annual Research Meeting. June 2021 (Virtual)

Jazowski SA, Patrick SW, **Dusetzina SB.*** The Rise and Fall of Prescription Fentanyl. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020 All Access. September 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19.

Jazowski SA, Nshuti L, **Dusetzina SB.*** Trends in Formulary Coverage and Point-of-Sale Prices of Filgrastim Products. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020 All Access. September 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19. Spotlight Poster Winner in the Biologics and Biosimilars Category.

Jazowski SA, Wilson L, **Dusetzina SB,*** Zafar SY, Zullig LL. Role of High-Deductible Health Plans on the Use of Lenalidomide. International Conference on Pharmacoepidemiology & Therapeutic Risk Management 2020. Sept 16-17, 2020. Virtual; in-person meeting canceled due to COVID-19.

Jazowski SA, **Dusetzina SB.*** Trends in the Promotion and Utilization of Programmed Death Receptor-1 Blocking Antibodies. Thomas M. Carsey Graduate Student Symposium. Chapel Hill, NC. November 8, 2019.

Jazowski SA, **Dusetzina SB.*** Trends in the Utilization of Short-acting Filgrastim following the United States Market Launch of the First Biosimilar. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Philadelphia, PA. August 24-28, 2019.

Jazowski SA, **Dusetzina SB.*** Trends in the Promotion and Utilization of Programmed Death Receptor-1 Blocking Antibodies. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Philadelphia, PA. August 24-28, 2019.

Winn AN, Keating NL, Trogdon J, Basch E, **Dusetzina SB***. Association between Chemotherapy Provider Competition and Access, Cost and Quality of Care for Medicare Beneficiaries with Cancer. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Mitchell A, Winn AN, **Dusetzina SB***. Temporal Association of Industry Payments and Prescribing Changes in Oncology. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Mitchell A, Kinlaw A, Sanoff HK, Basch E, Lund J, Peacock-Hinton S, **Dusetzina SB***. Cancer Patients Receive Higher-Priced Chemotherapy When Treated in Private Practice Compared to Academic Institutions. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Jazowski SA, **Dusetzina SB***. Identifying Off-Label Promotion of Cancer Pain Management Opioids in Open Payments. AcademyHealth Annual Research Meeting, June 25, 2018, Seattle, WA.

Higginbotham L, Jazowski SA, Adamson A, **Dusetzina SB***. Uptake of Immunotherapy Among Medicare Beneficiaries with Advanced Melanoma. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

Dusetzina SB, Jazowski SA, Cole, AL, Nguyen J. Coverage and out-of-Pocket Spending on Brand Versus Generic/Biosimilar Specialty Drugs in Medicare Part D. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

Savitz S, Trogdon J, Bailey S, Jones S, **Dusetzina SB**, Stearns S. Evaluation of Patient-Clinician Communicating during Decision Making for Stable Angina. AcademyHealth Annual Research Meeting, June 24, 2018, Seattle, WA.

Dusetzina SB, Owino H, Ansari S, Glickman SW. Post-Discharge Medicaid Spending and Health Services Use for Patients with Serious Mental Illness Treated at an Emergency Department Versus a Dedicated Community Mental Health Center. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA

Roberts A, Saloner B, **Dusetzina SB**. Utilization and Costs of Buprenorphine for Opioid Use Disorder: Trends from 2003-2015. AcademyHealth Annual Research Meeting, Jun 25-27, New Orleans, LA.

Olszewski AJ, **Dusetzina SB**, Davidoff AJ, Trivedi AN. Closure of Medicare Part D Coverage Gap by the Affordable Care Act and Use of Oral Anti-Myeloma Agents. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL.

Rotenstein L, **Dusetzina SB**, Keating NL. Out-of-Pocket Spending Not Associated with Drug Value for Oral Oncolytics Reimbursed By Commercial Insurers, 2007-2014. American Society of Clinical Oncology Annual Meeting, June 2-6, Chicago, IL. (Poster Discussion Selection)

Roberts M, **Dusetzina SB***. The Effect of a Celebrity Health Disclosure on Demand for Health Care: Trends in BRCA Testing and Subsequent Health Services Use. American Society of Prevention Oncology. March 12-14, 2017 at the Grand Hyatt Hotel in Seattle, Washington.

Barber EL, Van Le L, **Dusetzina SB***. Neoadjuvant chemotherapy versus primary debulking surgery: A propensity score matched cohort analysis of survival. Society of Gynecologic Oncology SGO 48th Annual Meeting on Women's Cancer. March 11-15, 2017, National Harbor, MD.

Smitherman AB, Mohabir D, Wilkins TM, Blatt J, Nichols HB, **Dusetzina SB***. Early Post-therapy Prescription Drug Usage among Survivors of Childhood Cancers. ASCO Cancer Survivorship Symposium. January 27-28, 2017. San Diego, CA.

Chou Y, **Dusetzina SB***. Trends in Erlotinib Use for Non-Small Cell Lung Cancer, 2007-2012. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Cole AL, Sanoff HK, **Dusetzina SB.*** Uptake and Cost of Capecitabine versus 5-FU Among Commercially-Insured Colorectal Cancer Patients. 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Dublin, Ireland, August 26, 2016.

Cole AL, Sanoff HK, **Dusetzina SB.*** Uptake and cost of capecitabine among commercially-insured colorectal cancer patients. International Society for Pharmacoeconomics and Outcomes Research, Washington D.C., May 2016. *Poster Award Finalist.*

Cole AL, Sanoff HK, **Dusetzina SB.*** Uptake and cost of capecitabine among commercially-insured colorectal cancer patients. UNC Eshelman School of Pharmacy Graduate Student Receipt, April 2016. *Poster Award Winner, 2nd Place.*

Winn AN, Keating NL, **Dusetzina SB***. Factors Associated with the Initiation and Use of Tyrosine Kinase Inhibitors Among Medicare Beneficiaries with Chronic Myeloid Leukemia. Academy Health Annual Research Meeting, Boston, MA. June 27, 2016.

Mahendraratnam N, **Dusetzina SB**, Farley JF. Early Impact of Medicaid Expansion on Prescription Drug Utilization and Spending. Academy Health Annual Research Meeting, Boston, MA. June 27, 2016.

Mitchell A, Basch EM, **Dusetzina SB***. Financial ties to industry are prevalent among National Comprehensive Cancer Network guideline authors. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016 (Poster Discussion Selection).

Falchook AD, Fang T, **Dusetzina SB**, Basak R, Hanson L, Selvam N, Chen RC. Use of Supportive Care at End-of-Life for Patients Younger than 65 with Incurable Cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016 (Poster Discussion Selection).

Knight TG, Deal AM, Muss HB, **Dusetzina SB**, Chol SK, Bensen JT, Williams GR. Financial distress among older versus younger adults with cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 4, 2016.

Kilfoyle KA, Rahangdale L, **Dusetzina SB***. Human papillomavirus (HPV) vaccine uptake among commercially insured postpartum women, 2006 – 2012. American Congress of Obstetricians and Gynecologists, Washington D.C., May 14-17, 2016.

Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, **Dusetzina SB***. Investigating Racial Disparities in Use of NK1 Receptor Antagonists to Prevent Chemotherapy-Induced Nausea and Vomiting Among Women with Breast Cancer. American Society of Clinical Oncology Quality Care Symposium, Phoenix, AZ, February 26-27, 2016.

Chou Y, Rosenstein DL, **Dusetzina SB***. Stage-Specific Incident Antidepressant Use and Adherence among Older Women with Breast Cancer. AcademyHealth, Minneapolis, MN. June 14-16, 2015

Chou Y, Winn AN, Rosenstein DL, **Dusetzina SB***. Estimating the Impact of a Breast Cancer Diagnosis on Antidepressant Adherence. 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA, August 2015

Check DK, Samuel C, Rosenstein DL, **Dusetzina SB***. The Association Between Early Symptom Management, Hospice Use, and Intensity of End-of-Life Care Among Elderly Women with Breast Cancer. AcademyHealth, Minneapolis, MN. June 14-16, 2015

Dusetzina SB, Tyree S, Meyer AM, Carpenter WR. Performance of Methods for Linking Registry Data to Insurance Claims when Unique Identifiers are Unavailable. AcademyHealth, San Diego, CA. June 7-10, 2014.

Roberts M, **Dusetzina SB.*** Trends in Oncotype DX use and per-use patient and insurer costs. AcademyHealth, San Diego, CA. June 7-10, 2014.

Lewis SE, Liu T, **Dusetzina SB.*** The Association between Age and Receipt of Comprehensive Diabetes Care. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Stevenson DG, **Dusetzina SB**, O'Malley AJ, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP, Huskamp HA. Potentially Inappropriate Medication Use as Nursing Home Residents Transition between the Hospital and Nursing Home. AcademyHealth, San Diego, CA. June 7-10, 2014.

Winn A, Keating NL, Lin P, Huskamp HA, **Dusetzina SB*** Orally Administered Cancer Drugs for Medicare Beneficiaries: Implications for Out-of-Pocket Spending Among Patients with Chronic Myeloid Leukemia. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Kum H, Krishnamurthy A, **Dusetzina SB**. Privacy-preserving Interactive Record Linkage: Privacy beyond Anonymity. AcademyHealth Annual Research Meeting, San Diego, CA. June 7-10, 2014.

Dusetzina SB, Mack C, Stürmer T. The Impact of Time Specific-Propensity Score Estimation on Estimates of the Comparative Effectiveness of Second Generation Antipsychotics. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, Aug 15-28, 2013.

Dusetzina SB, Mack C, Stürmer T. The Impact of Time Specific-Propensity Score Estimation on Estimates of the Comparative Effectiveness of Second Generation Antipsychotics. Academy Health Annual Research Meeting, Baltimore, MD. June 24, 2013.

Dusetzina SB, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. The Quality of Initial Medication Prescribing for Children with Bipolar I Disorder 27th ICPE: International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago IL August 14-17, 2011.

Dusetzina SB, Gaynes BN, Farley JF, Weinberger M, Sleath BL, Hansen RA. Age Related Treatment Differences Among Children with Bipolar Spectrum Disorders. International Society of Pharmacoeconomics and Outcomes Research Meeting, Atlanta, GA. May 15-19, 2010.

Dusetzina SB, Hansen RA, Pudlo A, Gaynes BN. The Feasibility of a Community Pharmacy-Based Intervention to Reduce Barriers to Antidepressant Adherence - Lessons Learned from a Pilot Study National Research Service Award Trainees Meeting, Chicago, IL. June 27- 30, 2009.

Dusetzina SB, Hansen RA, Song L, Gaynes, BN, Tu W, Murray MD. Depression Affects Adherence Measurement but Not the Effectiveness of an Adherence Intervention in Heart Failure Patients. American Pharmacists Association Annual Meeting, San Antonio, TX. April 3 – 6, 2009.

Dusetzina SB, Farley JF. The Influence of Medicare Part D on Medicaid Prescription Expenditures and Utilization. American Pharmacists Association Annual Meeting, San Diego, California. Mar 14 – 17, 2008.

f) Teaching Activities

PhD Program Director, Health Policy & Health Services Research (Vanderbilt)	2019 - Present
Research Immersion Area Lead (Vanderbilt University School of Medicine)	2020 - Present

Vanderbilt University School of Medicine

Term	Course number, title, type	Enrollment	Responsibility
Spring 2024	HPOL 8540: Introduction to Healthcare Database Research	25	Course Director 36 contact hours
Spring 2022	HPOL 8540: Introduction to Healthcare Database Research	12	Course Director 36 contact hours
Spring 2022	Foundations in Health Policy	90	2 lecture hours
Fall 2021	Clinical Informatics	25	Instructor
Spring 2019, 2020, 2021, 2022, 2023, 2024	Drug and Device Course, Vanderbilt School of Medicine	20	Instructor 1 lecture hour
Fall 2019, 2020, 2021	Financial Toxicity and Access to Care (University of Tennessee College of Pharmacy)	50	Instructor 1 lecture hour
Fall 2020, Spring 2021	PhD Student Seminar	3	Course Coordinator
Fall 2021, Spring 2022, Spring 2023	Introduction to U.S. Health Care Policy, Undergraduate	30	Instructor 1 lecture hour
Fall 2020	Health Care Under the Trump Administration, Undergraduate	30	Instructor 1 lecture hour

Fall 2019	Universities Allied for Essential Medicines Panel Discussion, Undergraduate Organization	30	Panelist 1 lecture hour
Fall 2019	VUSM Medical Ethics, Law, and Policy Group	80	Instructor 1 lecture hour
Spring 2019, 2020, 2021, 2022, 2023, Fall 2023, 2024	PUBH 5512: Decision Analysis in Medicine and Public Health, elective course for Masters in Health Policy Concentration and PhD in Health Policy	15	3 lecture hours
Fall 2018, 2019, 2020, 2021	HODH 3231: Introduction to Health Services, Undergraduate elective	23	Instructor 1 lecture hour
Fall 2018, 2019, 2020, 2021, 2022, 2023, 2024	PUBH 5520: Introduction to Health Policy, 3 credit hours, required Masters in Health Policy Concentration	24	Instructor 2 lecture hours
Fall 2018	Nikpay Health Policy Course, 3 credit hours, Undergraduate elective	20	Instructor 1 lecture hour
Spring 2018, 2019, 2020, 2022, 2023, 2024	PUBH 5525: Health Economics, Economics of Prescription Drugs, 2 credit hours, required Masters in Health Policy Concentration and PhD in Health Policy	10	Instructor 2 lecture hours, 1 lab hour
Summer 2018; Fall 2023	Grand Rounds: Vanderbilt University School of Medicine	100	Instructor 1 lecture hour
Fall 2024	Clinical Didactics. Department of Radiation Oncology, Vanderbilt University Medical Center	25	1 lecture hour
Fall 2024	Health Outcomes and Research Program Monthly Meeting. Vanderbilt University Specialty Pharmacy	30	1 lecture hour

UNC – Eshelman School of Pharmacy

Term	Course number, title, type	Enrollment	Responsibility
Fall 2017	DPOP 899, Division Seminar	10	Instructor 3 lecture hours

Fall 2016	DPOP 804 / HPM804, Introduction to Healthcare Database Research, 3 credit hours, required Ph.D. course (DPOP), open elective	30	Course Director 24 lecture hours / 39 contact hours
Fall 2016	PHCY 609, The US Healthcare System, 2 credit hours, required PharmD course	165	Instructor 3 lecture hours
Fall 2016	DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective	15	Instructor 1 lecture hour
Spring 2015	DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course	15	Instructor 3 lecture hours
Fall 2014	DPOP 806: Pharmaceutical Policy, 3 credit required Ph.D. course and PharmD elective	15	Instructor 1 lecture hour
Spring 2013	DPOP 870, Pharmaceutical Outcomes Research, 3 credit required PhD course	20	Instructor 3 lecture hours

UNC – Gillings School of Global Public Health

Fall 2017	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2017	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour
Fall 2017	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour
Fall 2017	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2017	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2016	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2016	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour
Fall 2016	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour

Spring 2016	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2016	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2015	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Fall 2015	HPM 766 - Equity in Cancer Care Quality, 3 credit hours, PhD elective	15	Instructor 1 lecture hour
Fall 2015	EPID 771: Cancer Epidemiology Methods, 3 credit Ph.D. elective	20	Instructor 1 lecture hour
Spring 2015	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2015	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Spring 2015	EPID 766: Epidemiologic Research Using Healthcare Databases, 3 credit Ph.D. elective course	30	Instructor 4 lecture hours
Spring 2015	HPM 781: Comparative Effectiveness Research Methods, 3 credit Ph.D. elective course	15	Instructor 1 lecture hour
Fall 2014	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Spring 2014	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour
Spring 2014	PUBH 701: Cost Effectiveness in Context, 3 credit elective course	25	Instructor 1 lecture hour
Spring 2014	EPID 893: Pharmacoepidemiology Seminar, 3 credit elective course	25	Instructor 1 lecture hour
Fall 2013	HPM 754 - Health Care in the United States: Structure and Policy, 3 credit hours, required residential and executive masters students	60	Instructor 1 lecture hour
Spring 2013	HPM 781: Comparative Effectiveness Research Methods, 3 credit Ph.D. elective course	15	Instructor 1 lecture hour
Spring 2013	HPM 873: First Year PhD Seminar, 3 credit required Ph.D. course	15	Instructor 1 lecture hour

UNC – School of Medicine

Fall 2017	MD/PhD Program Research Seminar	50	Instructor 1 lecture hour
Spring 2017	GI Epi Conference, Seminar	30	Instructor 1 lecture hour
Spring 2017	Oncology Faculty Meeting	20	Guest Presentation 0.5 lecture hours

UNC – Carolina Health Informatics Program

Fall 2017	INL 890, Health Informatics Seminar	20	Instructor 1 lecture hour
-----------	-------------------------------------	----	------------------------------

Advising Activities**Vanderbilt University, PhD in Health Policy Ph.D. Program Advisor**

2021 – Present	<u>Robert Besaw</u>
2022 – 2024	<u>Khrysta Baig</u>

Vanderbilt University, PhD in Health Policy Dissertation Committee Member

2020 – 2024	<u>Nathaniel Tran</u> (Co-Advisor with Gilbert Gonzales)
2021 – 2024	<u>Dennis Lee</u>
2023 – Present	<u>Emma Achola</u>
2024 – Present	<u>Sharon Fernandez</u>

Vanderbilt University, Medical Students, Research Immersion

2019 – 2021	<u>Alexandra Erath</u>
2024 – Present	<u>Alvina Liang</u>
2024 – Present	<u>Jenny Wu</u>

Vanderbilt University, Masters in Public Health, Health Policy

2020-2021	<u>Avirath Vaidya</u>
2023-2024	<u>Elias Mihan</u>
2023-Present	<u>Nadia Syed</u>
2024-Present	<u>Brian Duval</u>
2024-Present	<u>William Bunce</u>

Vanderbilt University, Masters Program in Medicine, Health & Society

2018 – 2019	<u>Lauren Taylor</u> – Thesis: Evaluating Financial Burdens and Cost-Related Nonadherence in Patients with Chronic Blood Cancers
-------------	--

UNC Eshelman School of Pharmacy Pharmaceutical Outcomes and Policy Ph.D. Program Advisor

2015 – 2020	<u>Matt Dixon</u> – Thesis: Effect of Colorectal Cancer on Antidepressant Medication Utilization, and the Factors Associated with Discontinuation Among Medicare Patients <u>Honors</u> : Cancer Care Quality Post-Doctoral Fellowship, UNC <u>Current Position</u> : Associate Director for Worldwide Health Economics and Outcomes Research – Colorectal Cancer, BMS
2015 – 2018	<u>Ashley Cole</u> – Thesis: Comparative Safety and Healthcare Resource Utilization Associated with First-Line Treatments for Chronic Myeloid Leukemia.

Honors: NRSA Pre-Doctoral Fellowship, Cecil G. Sheps Center for Health Services Research, UNC; American Foundation for Pharmaceutical Education (AFPE) Pre-Doctoral Fellowship in Pharmaceutical Sciences
Current Position: Research Director at GSK

- 2015 – 2018 Nirosha Mahendraratnam Thesis: Optimizing Antiemetic Use to Prevent Chemotherapy Induced Nausea and Vomiting: Lessons Learned with Big Data and Modeling.
Honors: Awarded BMS Pre-Doctoral Fellowship
First Post-Graduate Position: United States Food and Drug Administration
Current Position: Director of Real-World Evidence Strategy, Aetion
- 2014 – 2018 Yi-Ting (Zoey) Chou – Thesis: Accessibility and Affordability of High Priced Drugs in Advanced Non-Small Cell Lung Cancer.
Current Position: Post-doctoral fellow at UCSF
- 2014 – 2017 Robert Overman – Thesis: Prediction and Utility of a Clinical Fracture Risk Score in Administrative Claims.
Current Position: Data Scientist, Novartis Inc.
- 2015 – 2017 Mrudula Borse – Thesis: Comparative Effectiveness and Safety of Anticoagulants in the Management of Venous Thromboembolism in Elective Major Orthopedic Surgery Patients.
Current Position: Manager in the Health Economics & Market Access division of Ethicon, Inc.

UNC Eshelman School of Pharmacy Pharmacotherapy and Experimental Therapeutics Ph.D. Dissertation Committee Member

- 2016 – 2019 Olivia Dong – Thesis: Preemptive Pharmacogenomic Testing with DNA2RX™ in Cardiac Catheterization Laboratory Patients (Expected Completion, May 2018)
Current Position: Post-Doctoral Research Fellow, Duke

UNC Eshelman School of Pharmacy, PharmD Honors Program Advisor

- 2015 – 2017 Steven Otto
 2015 – 2017 Hugh Heldenbrand

Carolina Health Informatics Program (CHIP), Masters in Informatics

- 2015 – 2017 Kathryn Morbitzer

UNC School of Medicine

- 2014 – 2017 Andrew B. Smitherman, MD and Research Fellow
 Division of Pediatrics and Hematology/Oncology, UNC School of Medicine
Honors: Awarded St. Baldrick's Foundation fellowship
Role: Primary Research Mentor
Current Position: *Tenure Track Assistant Professor, University of North Carolina at Chapel Hill, School of Medicine, Pediatric Hematology / Oncology; Medical Director for UNC Adolescents and Young Adults Oncology Program*

- 2015 – 2018 Aaron Mitchell, MD and Research Fellow
 Division of Hematology/Oncology, UNC School of Medicine
Honors: Awarded a post-doctoral fellowship from the Cecil G. Sheps Center for Health Services Research
Role: Research Co-Mentor with Ethan Basch (Hematology/Oncology)
Honors: ASCO Merit Award, 2017; Conquer Cancer Foundation, Outstanding Fellow Award, North Carolina Oncology Association, Pope Clinical Trainee Award
Current Position: *Assistant Professor, Memorial Sloan Kettering Cancer Center*
- 2017 – 2018 Laura Higginbotham, MD and Research Fellow
 Chief Resident, Preventive Medicine, UNC School of Medicine
Masters Thesis: Immunotherapy in Advanced Stage Melanoma: Patterns of Use and Effectiveness
Role: Research Co-Mentor with Charles Poole (Epidemiology)
Current Position: Physician, United States Food and Drug Administration, Office of New Drugs
- 2015 – 2017 Danielle Mohabir, MD/PhD Student
 UNC School of Medicine and Department of Health Policy and Management
Role: Summer Research Rotation Mentor

Gillings School of Global Public Health, Department of Health Policy and Management Ph.D. Program

Advisor

- 2018 – 2021 Neela Kumar – Thesis: The Effects of High Deductible Health Plans on Adherence and Cost Sharing for Adults with Diabetes
 Current Position: Director, Payer & Real World Evidence, AstraZeneca
- 2016 – 2021 Shelley Jazowski – Thesis: Association between Low-income Subsidies and Racial Disparities in Anticancer Treatment Use and Outcomes Among Medicare Beneficiaries with Multiple Myeloma.
Honors: Pre-doctoral fellow, Duke Clinical Research Institute
Current Position: *Assistant Professor, Wake Forest School of Medicine*
- 2013 – 2017 Aaron Winn – Thesis: The Impact of Market Structure on Oncology Care.
Honors: Royster Society of Fellows, 5 Year Merit Scholarship
Current Position: *Associate Professor with Tenure, Medical College of Wisconsin, School of Pharmacy*
- 2013 – 2016 Devon Check – Thesis: Assessing Racial Disparities in Quality of Chemotherapy-Induced Side Effect Management among Medicare Beneficiaries with Early Stage Breast Cancer.
Honors: Health Care Delivery Post-Doctoral Fellow, Kaiser Northern California
Honors: Jean G. Yeats Outstanding Doctoral Student Award
First Post-Graduate Position: *Delivery Science Fellow at the Kaiser Permanente Northern California Division of Research*
Current Position: *Assistant Professor, Duke University, Department of Population Health Sciences*

Gillings School of Global Public Health, Department of Health Policy and Management Dr.Ph. Program

Advisor

- 2015 – 2018 David Nimke – Thesis: Do as I Say, Not as I Do: A cohort study of commercially ensured families and the relationship between parental and child adherence and persistence with chronic medication.
- 2015 – 2019 Dana Wollins – Thesis: Integrating Doctor-Patient Cost Discussions into Oncology Practice. (Expected graduation May 2019)

Gillings School of Global Public Health, Department of Health Policy and Management Ph.D.

Dissertation Committee Member

- 2018 – 2022 Wendi (Elkins) Rotunda – Thesis: Impact of High Costs for Oral Anticancer Drugs: Access, Death, and Net Worth

Current Position: Research Public Health Analyst; RTI, International
- 2017 – 2019 Natalie Ernecoff – Thesis: The Impact of Palliative Practices of Non-Specialty Palliative Care Providers on Utilization among Patients with Serious Illness
Current Position: Associate Policy Researcher, RAND Corporation
- 2017 – 2019 Paul Shafer – Thesis: Effect of the Affordable Care Act on Utilization of Emergency and Primary Care.
Current Position: Assistant Professor of Health Policy, Boston University
- 2017 – 2022 Hadi Beyhaghi - Thesis: Evidence-Based Prescribing of a Ipilimumab vs. Dacarbazine for Advanced Melanoma, Integrating treatment effectiveness and patient values.

Current Position: Medical Director, Medical Affairs at NOVAVAX
- 2015 – 2018 Sam Savitz – Thesis: Health literacy in treatment selection & medication adherence: Application to stable angina.
First Post-Graduate Position: *Delivery Science Fellow at the Kaiser Permanente Northern California Division of Research*

Current Position: *Collaborative Scientist at Mayo Clinic*
- 2014 – 2020 Lisa Selker – Thesis: Impact of Black Box Warnings on Drug Prescribing.
- 2013 – 2016 Megan Roberts – Thesis: Racial Variation in the Use of Oncotype Dx Testing Among Women with Breast Cancer.
First Post-Graduate Position: *Post-doctoral trainee, NCI*
Current Position: *Tenure-Track Assistant Professor, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy; Director, Implementation Science in Precision Health & Society*
- 2013 – 2016 Sarah Lewis – Thesis: Assessing Quality of Non-Cancer Chronic Care and Medication Adherence for Comorbidities among Prostate Cancer Survivors.
First Post-Graduate Position: *Prevention Effectiveness Fellow, Office of the Assistant Secretary for Planning and Evaluation, Health Policy*
Current Position: Social Science Research Analyst, CMMI

2014 – 2016 Regina Rutledge – Thesis: The Role of Provider, Site of Care and Contraceptive Type in Birth Spacing.

Current Position: *Research Public Health Analyst at RTI International*
 2014 – 2016 Todd Durham – Thesis: Can Novel Competing Risks Prediction Models Improve Population Health in Adults with Newly Diagnosed Atrial Fibrillation?
Current Position: *Biostatistician and Decision Scientist, Novan, Inc.*

Gillings School of Global Public Health, Epidemiology Ph.D. Dissertation Committee Member

2014 – 2017 Greta Bushnell – Thesis: Pediatric Anxiety: Pharmacotherapy and Psychotherapy and Serious Adverse Outcomes.

Honors: *F31 Dissertation Awardee NIMH, New Investigator Award, American Society of Clinical Psychopharmacology (2016)*

Current Position: *Post-Doctoral Fellow, Psychiatric Epidemiology Training program (T32) at Columbia University, Department of Epidemiology*

2014 – 2016 Nadya Belenky – Thesis: Effects of Medicare Part D Implementation on Medicaid-Medicare Dual Eligibles with HIV

Current Position: *Post-Doctoral Fellow, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill*

Gillings School of Global Public Health, Department of Health Policy and Management MHA Advisor

2017 – 2018 Kristen Leloudis – Thesis: Developing and Evaluating Novel Policy Solutions to Increase Access to Hepatitis C Medications for Incarcerated Patients

2016 – 2017 Carrie Blanchard

2016 – 2017 Wen Lin – Thesis: Comparisons of Value Frameworks for Oncology Drugs and Implications for Performance Based Pricing

Gillings School of Global Public Health, Department of Health Policy and Management BSPH Advisor

2016 – 2017 Victoria Hamby - Thesis: Understanding the Impact of Step Therapy Protocols on Physicians' Prescribing Decisions, Perceptions of Quality of Care, Autonomy, and Job Satisfaction within North Carolina

Honors: Graduated with Highest Honors; 2017 Arnold D. Kaluzny Award for Excellence in Undergraduate Research

Current Position: *Advisory Staff, EY*

UNC School of Nursing Ph.D. Dissertation Committee Member

2017 – 2019 Esita Patel – Thesis: Impact of State Level Nurse Practitioner Scope of Practice Regulation on Primary Care Diabetes Patient Utilization and Outcomes

First Post-Graduate Position: Post-doctoral Fellowship at Johns Hopkins School of Public Health

Current Position: Sr. Manager of Advanced Practice Outcomes and Analytics, Atrium Health

Post-Doctoral Trainees

Youngmin Kwon, PhD June 2024 – Present
Prior: PhD Program in Health Policy and Management, University of Pittsburgh

Shelley A. Jazowski, PhD June 2021 – Present
Prior: PhD Program in Health Policy and Management, UNC Chapel Hill
Current Position: Tenure Track Assistant Professor, Wake Forest

Xuanzi (Shirley) Qin, PhD December 2020 – July 2022
Prior: PhD Program in Health Services, Policy, and Administration, University of Minnesota
Current Position: Tenure Track Assistant Professor, University of Maryland

Shellie Ellis, PhD
Prior: PhD Program in Health Policy and Management, UNC Chapel Hill 2014
Current Position: *Associate Professor, with Tenure, University of Kansas School of Medicine*

g) Grant Support – Active

NIDDK - 1R01DK141666-01 (Lipska) 01/01/2025 – 11/30/2028
Insulin Affordability: Unpacking the Impact of the Inflation Reduction Act on Diabetes Outcomes and Equity in Medicare
The proposed project will evaluate the real-world implications of the IRA by leveraging rigorous quasi-experimental methods applied to data from OptumLabs Data Warehouse linked with Medicare fee-for-service (100% sample) claims from 2021-2022 (pre-IRA) and 2023-2024 (post-IRA).
Role: Co-I

Arnold Ventures (Dusetzina) 01/01/2024 – 05/31/2026
Trends in Oncology Drug Prices, Coverage, and Potential Savings in Medicare Part D with the Implementation of the Inflation Reduction Act
In the proposed research plan, we will evaluate changes in drug pricing, insurer benefit design, and medication use among Medicare beneficiaries during the initial years of Inflation Reduction Act implementation.
Role: PI

Commonwealth Fund & Arnold Ventures (Mitchell; Dusetzina) 09/01/2023 – 08/31/2025
Prescription Drug Prices, Financial Incentives, and Cancer Care Quality in Medicare Part B
The overall goal of this proposal is to evaluate whether, and to what extent, the “perverse incentives” of high prescription drug prices adversely affect cancer care quality and costs to beneficiaries and the Medicare program.
Role: Co-PI

National Cancer Institute 1P01CA281850-01A1 (Keating/Landrum) 09/15/2024 – 08/31/2029
Understanding Integration in Oncology Care and Association with Quality and Outcomes
Project 4: Care Integration for Patients with Cancer Using Specialty Pharmacies.
This project aims to examine the integration of specialty pharmacies into systems/hospitals and independent practices and its impact on patients’ use of and adherence to orally-administered anticancer and supportive care drugs.
Role: Co-PI, Program Project 4

NIDDK 1R01DK139133-01 (Maciejewski) 07/01/2024 – 04/30/2028
 Developing robust anti-Obesity Medication Implementation approaches to maximize population health (the DOMINO study) The study’s specific aims are to: Aim 1: Use data from 2009-2023 from the multi-site STAR PCORnet Network to understand the demographic, clinical and provider characteristics of eligible patients that are associated with AOM receipt. Aim 2: Identify key factors influencing AOM use at the patient, provider, and system levels.
 Role: Co-I

NIDDK 1R01DK141666-01 (Lipska) – JIT Submitted 10/01/2024 – 09/30/2029
 Insulin Affordability: Unpacking the Impact of the Inflation Reduction Act on Diabetes Outcomes and Equity in Medicare. The study goals are to evaluate the real-world implications of the IRA using quasi-experimental methods and data from commercially insured and Medicare insured populations.
 Role: Co-I

Leukemia & Lymphoma (Dusetzina; Nicholas) 06/01/2022 – 05/31/2025
 Making the Right Choice: Medicare Plan Selection and Access to Cancer Care
 The proposed project evaluates the financial and health outcomes for individuals selecting different Medicare coverage options and how these outcomes vary by the presence and timing of a cancer diagnosis. The goal of this work is to identify opportunities to improve plan selection and reduce inequities in cancer care and outcomes.
 Role: PI

1R37CA264563-01A1 NCI (Mitchell) 7/01/2022 – 6/30/2027
 Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs
 Conflict of interest between physicians and the drug industry is common, increasing, and influences medical practice. The short-term project goal is to evaluate the association between industry payments and cancer care quality, patient outcomes, and costs. The long-term research goal is to understand the importance of physician-industry financial relationships within the US healthcare system.
 Role: Co-I

CMMI (RAND) Part D Senior Savings Model Evaluation 6/01/2021 – 9/30/2025
 This project will evaluate a change to the Medicare Coverage Gap Discount Program to allow participating Part D sponsors, through eligible enhanced alternative plans, to offer a Part D benefit design that includes predictable copays in the deductible, initial coverage, and coverage gap phases.
 Role: Co-I

2P30CA068485 (Park) NCI, Cancer Center Support Grant 09/01/2020 - 08/31/2027
 Support for cancer health services research collaborations, including SEER-Medicare studies and other related health outcomes or policy work.
 Role: Staff Investigator

Grant Support –Completed

K23DE028010-01A1 (Smith) NIDCR 04/01/2019 – 03/31/2024
 Developing an oral health screening tool for an integrated model of care to reduce treatment-related oral morbidity in head and neck cancer survivors
 Improve understanding of barriers to care and statistical infrastructure needed to implement a novel oral care model to support staff with a screening tool to identify patients at high risk for oral disease.
 Role: Co-Mentor (Effort in Kind)

1R01AG068606-01 (Keohane) NIA 09/01/2020 - 06/30/2024
 Diabetes, Dementia, and Aging at Home: The specific aims of this study are to: 1) Describe transitions into home-and-community-based services and nursing homes for older adults with diabetes and identify which factors, including dementia, limited social support, and insulin use, predict these transitions; 2) To evaluate whether more generous Medicaid home-and-community-based service coverage is associated with changes in days at home, inpatient and emergency room use, nursing home entry, and treatment for hypoglycemia; and 3) To assess whether beneficiaries with more generous Part D plan coverage or greater Part D subsidies are more likely to use simpler insulin options.
 Role: Co-I

Commonwealth Fund (Dusetzina) 09/01/2020 - 08/30/2023
 Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending. Document drug list and net price trends in Medicare and examine the relationship between average rebate size and Part D formulary placement, beneficiary cost sharing, and product market share within a drug class. Assess trends in list and net prices for Part D drugs after generic competition occurs and whether drugs with large rebates have more generous formulary coverage and less use of generic alternatives. Finally, we will explore pricing dynamics and market share for authorized generics, including their use relative to traditional brands and traditional generics for the same product.
 Role: PI

Arnold Ventures (Dusetzina) 09/01/2020 - 08/30/2023
 Co-funding for project: Evaluating the Role of Rebates on Medicare Formulary Coverage, Market Share, and Patient and Plan Spending.
 Role: PI

VUMC/ (Sachs) Laura and John Arnold Foundation 07/01/2020 - 06/30/2023
 State Medicaid Programs and the FDA's Accelerated Approval Pathway
 Role: Site PI/Co-I

RWJF (Dusetzina/Everson) Robert Wood Johnson Foundation 03/01/2020-11/30/2022
 Using Drug Pricing Tools to Inform Cost Conversations
 We will 1) conduct community engagement focus groups with patients, prescribers and the clinical staff that currently have medication cost conversations; 2) implement surveys to test and extend key themes emerging from focus groups in larger samples; and 3) implement a vignette-based fractional factorial experiment to investigate how key implementation decisions, prescription characteristics, and patient demographics influence providers' decision making and confidence in engaging in a cost conversation.
 Role: Co-PI

VUMC74193 (PI: Conti, Site PI: Dusetzina) Leukemia and Lymphoma Society 6/1/2016 – 12/31/2022
 Project: Assessing the value of cancer therapies among patients and providers.
 Measure the financial burden and contributors to financial burden among patient with blood cancers for developing patient, provider, or site level interventions.
 Role: Site PI; Co-Investigator

NIHCM (Mitchell) 1/01/2021 – 12/31/2021
 Can Conflict of Interest with the Drug Industry Harm Patients?
 Conflict of interest (COI) between physicians and the drug industry is common, increasing, and influences medical practice. However, whether COI can induce physicians to deliver care that is harmful

to patients is unknown. To address this question, we propose to assess whether physician COI is associated with selection of less-beneficial cancer treatments (objective 1) or with delivery of low-value cancer interventions (objective 2).

Role: Co-I (Effort in Kind)

20181785 (Dusetzina) Commonwealth Fund 09/01/2018 - 08/31/2021

Identifying cost and coverage barriers to Medicare beneficiary access to specialty drugs

The goal of this study is to identify rates of treatment initiation among Medicare beneficiaries prescribed medications to treat cancer, HIV, Hepatitis C, rheumatoid arthritis, and multiple sclerosis. We will also evaluate the relationship between drug prices, coverage, and adherence.

Role: PI

VUMC69249(PHP9000-20) (Dusetzina) Leukemia & Lymphoma Society 09/01/2018 - 08/31/2021

Identifying cost and coverage barriers to Medicare beneficiary access to specialty drugs

The goal of this study is to identify rates of treatment initiation among Medicare beneficiaries prescribed medications to treat cancer, HIV, Hepatitis C, rheumatoid arthritis, and multiple sclerosis. We will also evaluate the relationship between drug prices, insurance coverage, and adherence to prescribed medications.

Role: PI

VUMC69760 (KFF / Dusetzina) The Laura and John Arnold Foundation 10/01/2018 - 09/30/2020

Generic Exclusion and Non-Preferred Placement in Medicare Part D in 2016 and Trends over Time. The goal of this study is to evaluate incentives to use higher versus lower priced drugs within the Medicare Part D program and to better understand the uptake and use of generic drugs among older adults.

Role: PI

Patient Centered Outcomes Research Institute (PCORI) (PI: Ron Chen) – 2/1/2016 – 2/01/2019

Project: Optimizing the effectiveness of routine post-treatment surveillance in prostate cancer survivors To understand risks and benefits of post-treatment surveillance strategies for men with prostate cancer.

Role: Co-Investigator, Lead Methodologist (25% Years 1-3) (\$1,161,162)

American Cancer Society (PI: Dusetzina) – 7/1/2014-6/30/2017

Research Scholar Grant (R01-equivalent)

Project: Impact of Oral Cancer Parity Legislation on Use and Costs of Cancer Care (\$479,932)

Role: Principal Investigator (20% Years 1-2, 15% NCE)

R34 1R34MH107588 (PI: Glickman) - 9/1/2015-08/30/2017

National Institute of Mental Health (NIMH)

Project: Novel Use of Mobile Integrated Emergency Medical Services to Improve Outcomes of Mental Health Emergencies (\$400,399)

Role: Co-Investigator (Effort in-kind year 1, 20% Year 2)

Carolina's Collaborative Pilot Grant (PI: Willis) - 9/1/2017-8/30/2018

Project: Antibiotic prescribing in NC before and after an FDA boxed warning on fluoroquinolones in 2016

Role: Co-Investigator (Effort in Kind) (\$50,000)

550KR131607 (PI: Dusetzina) - 7/1/2016-6/30/2017

NC TraCS CER Program: Less is More? Evaluating Surveillance Patterns after Non-Operative Management Compared to Conventional Management for Older Individuals with Rectal Cancer (\$50,000)

Data@Carolina Course Development Grant Program (PI: Dusetzina) – 4/28/2016 – 8/01/2016

Project: Development of DPOP 804/HPM 804 course materials (\$9,449).

Role: Course Director / Developer

550KR101503 (PI: Chen) - 5/1/2015-4/30/2016

NC TraCS CER Program: Aggressive End-of-Life Care among Patients with Cancer under Age 65: Analysis of the HealthCore Integrated Research Database (\$50,000)

Role: Co-Investigator (In Kind, Year 1)

CERR11402 (PI: Reeder-Hayes) – 1/1/2015-12/31/2015

NC TraCS CER Program

Project: Comparative Effectiveness of Trastuzumab-Based Chemotherapy Regimens for Early Stage Breast Cancer (\$50,000)

Role: Co-Investigator (In Kind, Year 1)

NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) K12 Program

(PI: Dusetzina; KL2 PI: Orringer / Boggess) - 07/01/2013–06/30/2016

Role: Scholar (75% Years 1-3)

Project: Treating the whole patient: evaluating the use of depression treatments during the year following a new colorectal or breast cancer diagnosis.

HHS2902010000141 (PI: M. Alan Brookhart) – 9/1/2012-8/31/2014

Role: Co-Investigator (20% Year 1; 15% Year 2)

AHRQ DEcIDE Program. Developing and Evaluating Methods for Record Linkage and Reducing Bias in Patient Registries (\$1,112,042)

R01HS018960 (PI: G. Caleb Alexander) – 7/1/2010-6/30/2014

Role: Consultant (Effort in Kind Years 1-2; 15% Effort Years 3-4)

Assessing the Effect of FDA Advisories on Provider, Patient, and Firm Behavior

T32MH019733-17 (PI: Richard Frank / Haiden Huskamp) – 7/1/10-6/30/12

Role: Research Fellow / Trainee

National Institutes of Mental Health National Research Service Award (NRSA) Post-Doctoral Traineeship in Mental Health Services Research at the Department of Health Care Policy, Harvard Medical School.

T32HS000032-20 (PI: Timothy Carey) – 9/1/08-6/30/10

Agency for Healthcare Research and Quality (AHRQ) National Research Service Award (NRSA) T-32 Pre-doctoral Traineeship at the Cecil G. Sheps Center for Health Services Research, UNC-CH.

Honors and Awards

Emory Distinguished Keynote Speaker of Excellence	2024
Vanderbilt-Ingram Cancer Center 2023 Star Award	2024
VUMC Biomedical Science Impact Award (X2)	2024
National Academies of Sciences, Engineering and Medicine Committee Member	2024
VUMC Biomedical Science Impact Award (X2)	2023
Publication-of-the-Year Award, Academy Health	2023
VUMC Biomedical Science Impact Award (X2)	2022
Vanderbilt-Ingram Cancer Center 2021 Star Award	2021
VUMC Biomedical Science Impact Award (X1)	2021
VUMC Biomedical Science Impact Award (X2)	2020
Vanderbilt-Ingram Cancer Center 2019 Star Award	2020
VUMC Biomedical Science Impact Award (X2)	2019
National Academy of Medicine Emerging Leader	2019
Becker's Rising Stars – 66 Leaders in Healthcare Under 40	2019
Expert Witness for Senate Aging Committee Hearing on The Complex Web of Prescription Drug Prices: https://www.aging.senate.gov/hearings/the-complex-web-of-prescription-drug-prices-part-ii-untangling-the-web-and-paths-forward	2019
National Academies of Sciences, Engineering and Medicine Committee Member	2016, 2017
Study: Ensuring Patient Access to Affordable Drugs	
Invited Participant, President's Cancer Panel Workshop	2016, 2017
NRSA Post-Doctoral Fellowship in Mental Health Services Research	2010 - 2012
NRSA Pre-Doctoral Fellowship - Cecil G. Sheps Center for Health Services Research	2008 - 2010
Kathryne A. Brewington Graduate Research Award	2009
APhA-APRS ESAS Postgraduate Best Paper Podium Award (Finalist)	2009
Rho Chi Honor Society – UNC Eshelman School of Pharmacy	2008
Eshelman Fellowship – UNC Eshelman School of Pharmacy	2007
Golden Key Honor Society – UNC Chapel Hill	2007
Highest Quality Achievement Award – Rho, Inc.	2005
Reaching Above and Beyond Award – Rho, Inc.	2004

h) Professional Service

Commissioner, Medicare Payment Advisory Commission, May 2021 - Present
Faculty Advisory Council Member, Vanderbilt University School of Medicine, December 2020 - Present
Research Council Member, Tradeoffs Podcast, January 2021 - Present
E2PS Research Director, Vanderbilt University School of Medicine, June 2020 - Present
Invited participant, Listening Session with Seema Verma on Paying for Cures, July 2019
Special Expert, Health Economist Representative for the National Cancer Institute's Cancer Care Delivery Research Steering Committee, August 2018 - Present
Advisory Board Member, AHRQ NRSA Fellowship Program, UNC Chapel Hill, August 2018 - Present
NCI PDQ Adult Treatment Editorial Board – Financial Toxicity & Cancer, March 2018 - Present
ICER Midwest Comparative Effectiveness Public Advisory Council Member, March 2018 - Present
Panelist, Assessing the Public Health Impact of Prescription Drug Postmarket Safety Labeling Changes, Duke-Margolis Center for Health Policy, Washington DC, February 2018
Penn LDI Gene and Cell Therapy Symposium, Advisory Committee Member, January – September 2018
ASCO Organizing Committee Member, Pre-Conference Session on Cancer Economics, July 2017 - Present
Reviewer, Eshelman Institute for Innovation Student Pitch Day, November 2016
Graduate Program Visionary Committee, UNC Eshelman School of Pharmacy, April 2017 - Present

ASCO Health Services Research Oral Session Discussant, June 2016
 Ad-Hoc Grant Reviewer, American Cancer Society
 ASCO Antiemetics Guideline Panel Member

Invited Presentations

Einstein Cancer Epidemiology, Prevention and Control Program	December 2024
Mathematica	November 2024
New England Journal of Medicine / Harvard Symposium	October 2024
Meharry Vanderbilt Alliance	October 2024
University of Pennsylvania	September 2024
National Academy for State Health Policy	September 2024
Emory	May 2024
White House	April 2024
University of North Carolina at Chapel Hill	April 2024
2024 VBID Summit	March 2024
MD Anderson Cancer Center	February 2024
Stanford Health Policy Forum	October 2023
STAT Summit (Boston)	October 2023
University of Chicago, Department of Public Health Sciences	October 2023
Baker Institute for Public Policy, Rice University	October 2023
ASPE Visiting Scholars Series	July 2023
CP3 Pharmacoequity Conference, University of Pittsburgh	June 2023
Penn Leonard Davis Institute	May 2023
Hopkins Center for Drug Effectiveness and Safety	April 2023
Harvard Medical School	January 2023
Center for Drug Safety and Effectiveness, Johns Hopkins	January 2023
AcademyHealth Organizational Member Briefing, Topics in Health	October 2022
Breastcancer.org – Financial Toxicity of Breast Cancer	October 2022
IQVIA Institute for Human Data Science	October 2022
Stanford Health Policy, Advancing Health Equity Symposium	October 2022
National MS Society, What Does the New Drug Pricing Law Mean for You	August 2022
STAT - Democrats' Last Chance for Drug Pricing Reform	July 2022
IQVIA Institute for Human Data Science	May 2022
Yale School of Medicine	May 2022
Office of Health Economics 60 th Anniversary Event	April 2022
POLITICO Health Care Summit	March 2022
University of California, San Francisco	November 2021
Stanford University	November 2021
National Academy of Medicine, Promoting Health Equity in Cancer	October 2021
Charles C. Leighton, MD Memorial Lecture, University of Pennsylvania	April 2021
University of Washington	April 2021
Auburn University Harrison School of Pharmacy	February 2021
National Institutes of Health Joint Bioethics Colloquium	April 2020
National Academy of Medicine, Implications of Discarded Weight-Based Drugs	April 2020
Harvard Medical School Center for Bioethics	September 2019
Medical Grand Grounds, Oregon Health & Science University	June 2019
Center for Drug Safety and Effectiveness, Johns Hopkins	April 2019
Division of Health Policy and Insurance Research, Harvard Medical School	March 2019

Center for Pharmaceutical Policy and Prescribing, University of Pittsburgh	December 2018
Panelist, Brookings Institution, A Conversation with Seema Verma	October 2018
Center for Health Incentives & Behavioral Economics, Penn	September 2017
Fred Hutchison Cancer Center	July 2017
Duke Medical School, Department of Population Health Sciences	June 2017
American Society of Clinical Oncology, Economics of Cancer Care	June 2017
Vanderbilt School of Medicine	April 2017
University of Chicago, School of Medicine	December 2015
Dana Farber Cancer Institute	November 2015
Board of Trustees Meeting, UNC Chapel Hill	July 2015
Harvard Medical School, Department of Population Medicine	April 2015
Memorial Sloan Kettering Cancer Center	December 2014
Board of Visitors Meeting, UNC Eshelman School of Pharmacy	December 2014
Board of Visitors Meeting, UNC Lineberger Comprehensive Cancer Center	September 2014
Agency for Healthcare Research and Quality, Agency Meeting	July 2014
Center for Health Services Research in Primary Care, Durham Veterans Affairs	December 2013
University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics	March 2012
Perelman School of Medicine	
UNC, NC Translational and Clinical Sciences Institute	March 2012

Professional Association Membership and Service

AcademyHealth
 American Society of Health Economists
 International Society for Pharmacoepidemiology
 Abstract Reviewer – International Society for Pharmacoepidemiology
 Abstract Reviewer – Society for Medical Decision Making

Editorial Activities – Editorial Board Member

American Journal of Managed Care	September 2021 - Present
Journal of Health Politics Policy and Law - Special Issue Co-Editor	July 2021 - Present
JAMA Internal Medicine	March 2020 - Present
Journal of the National Cancer Institute	November 2017 - Present
Journal of Clinical Oncology – Special Series Co-Editor	November 2018 - Present

Editorial Activities – Journal Reviewer (Selected)

Annals of Internal Medicine	Cancer
Health Affairs	Health Services Research
Journal of the American Medical Association	JAMA Internal Medicine
Journal of Clinical Oncology	Journal of the National Cancer Institute
New England Journal of Medicine	Proceedings of the National Academy of Sciences

Awarded “Top Peer Reviewer” – Journal of the American Medical Association (2023)
 Awarded “Top Peer Reviewer” – JAMA Health Forum (2023)
 Awarded “Top Peer Reviewer” – JAMA Network Open (2023)
 Awarded “Exceptional Reviewer” – Annals of Internal Medicine (2020)
 Highest-Quality Peer Reviews - Journal of Managed Care + Specialty Pharmacy (2020)
 Awarded “Top Peer Reviewer” – JNCI Cancer Spectrum (2018)
 Awarded “Best Reviewer” – Pharmacoepidemiology and Drug Safety (2013-2016)